<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Open Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Open Gastroenterol</journal-id><journal-id journal-id-type="pmc-domain-id">2793</journal-id><journal-id journal-id-type="pmc-domain">bmjogastro</journal-id><journal-id journal-id-type="publisher-id">bmjgast</journal-id><journal-title-group><journal-title>BMJ Open Gastroenterology</journal-title></journal-title-group><issn pub-type="epub">2054-4774</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12258370</article-id><article-id pub-id-type="pmcid-ver">PMC12258370.1</article-id><article-id pub-id-type="pmcaid">12258370</article-id><article-id pub-id-type="pmcaiid">12258370</article-id><article-id pub-id-type="pmid">40659386</article-id><article-id pub-id-type="doi">10.1136/bmjgast-2024-001723</article-id><article-id pub-id-type="publisher-id">bmjgast-2024-001723</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Dyspepsia</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject></subj-group></article-categories><title-group><article-title>Bone health, renal outcomes, and iron deficiency anaemia in proton pump inhibitor versus histamine-2 receptor antagonist users: a retrospective cohort study based on TriNetX global collaborative network data</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="TP">To-Pang</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="MJ">Ming-Ju</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="CH">Cheng-Hsu</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6119-0587</contrib-id><name name-style="western"><surname>Tsai</surname><given-names initials="SF">Shang-Feng</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff5" ref-type="aff">5</xref><xref rid="cor1" ref-type="corresp"/></contrib><aff id="aff1"><label>1</label><institution content-type="department">Division of Endocrinology and Metabolism, Department of Internal Medicine</institution>, <institution>Show Chwan Memorial Hospital</institution>, <addr-line content-type="city">Changua city</addr-line>, <country>Taiwan</country></aff><aff id="aff2"><label>2</label><institution content-type="department">Division of Nephrology, Department of Internal Medicine</institution>, <institution>Taichung Veterans General Hospital</institution>, <addr-line content-type="city">Taichung</addr-line>, <country>Taiwan</country></aff><aff id="aff3"><label>3</label><institution content-type="department">Department of Post-Baccalaureate Medicine, College of Medicine</institution>, <institution>National Chung Hsing University</institution>, <addr-line content-type="city">Taichung</addr-line>, <country>Taiwan</country></aff><aff id="aff4"><label>4</label><institution content-type="department">PhD program, Tissue Engineering and Regenerative Medicine, College of Medicine</institution>, <institution>National Chung Hsing University</institution>, <addr-line content-type="city">Taichung</addr-line>, <country>Taiwan</country></aff><aff id="aff5"><label>5</label><institution content-type="department">Division of Clinical Informatics, Department of Digital Medicine</institution>, <institution>Taichung Veterans General Hospital</institution>, <addr-line content-type="city">Taichung</addr-line>, <country>Taiwan</country></aff></contrib-group><author-notes><fn><p><bold>Supplemental material:</bold> Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p></fn><fn id="fn1"><p>Additional supplemental material is published online only. To view, please visit the journal online (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1136/bmjgast-2024-001723" ext-link-type="uri">https://doi.org/10.1136/bmjgast-2024-001723</ext-link>).</p></fn><fn fn-type="COI-statement" id="fn5"><p>None declared.</p></fn><corresp id="cor1">Dr Shang-Feng Tsai; <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="s881056@gmail.com">s881056@gmail.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>13</day><month>7</month><year>2025</year></pub-date><volume>12</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">480095</issue-id><elocation-id>e001723</elocation-id><history><date date-type="received"><day>18</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>13</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>14</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-15 11:25:26.043"><day>15</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bmjgast-12-1.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="pdf" xlink:href="bmjgast-12-1.pdf"/><abstract><sec><title>ABSTRACT</title></sec><sec><title>Objective</title><p>Proton pump inhibitors&#8217; (PPIs) widespread use raises concerns about bone health, renal outcomes, and iron deficiency anaemia (IDA). We aim to address these concerns via comprehensive matching.</p></sec><sec><title>Methods</title><p>Using TriNetX 1:1 propensity score matching (PSM), we compared PPI and histamine-2 receptor antagonist (H2RA) users in terms of renal outcomes (eg, estimated glomerular filtration rate and chronic kidney disease (CKD) stages), bone health (osteoporosis and fractures), and IDA (International Classification of Diseases codes and laboratory values).</p></sec><sec><title>Results</title><p>After 1:1 PSM, 126&#8201;155 matched patients (mean age 59 years, estimated glomerular filtration rate (eGFR) 84&#8211;86&#8201;mL/min/1.732&#8201;m&#178;) with fewer comorbidities (24% diabetes, 18% ischaemic heart disease, 11% heart failure, 11% nicotine dependence, 4% osteoporosis) were included. After follow-up, patients in the PPI group had a significantly lower mean eGFR compared with those in the H2RA group (75.74&#8239;&#177;&#8239;37.56 vs 78.60&#8239;&#177;&#8239;35.23&#8201;mL/min/1.732&#8201;m&#178;, p&lt;0.001). The PPI group also demonstrated significantly increased risk of CKD progression, with HR of 1.137 (95% CI 1.120 to 1.154) for stage 3a, 1.260 (95% CI 1.235 to 1.286) for stage 3b, 1.316 (95% CI 1.288 to 1.345) for stage 4, and 1.785 (95% CI 1.718 to 1.854) for stage 5. In addition, PPI users exhibited higher risks of osteoporosis (HR 1.119, 95%&#8201;CI 1.071 to 1.169) and major bone fractures (HR 1.153, 95%&#8201;CI 1.110 to 1.198). The risk of IDA was also significantly elevated in the PPI group (HR 1.761, 95%&#8201;CI 1.691 to 1.835). Findings were consistent across all subgroups and regions.</p></sec><sec><title>Conclusion</title><p>In this large matched cohort, PPI use was associated with higher risks of CKD, osteoporosis, fractures, and IDA. Clinicians should monitor long-term PPI users for these potential adverse effects.</p></sec></abstract><kwd-group><kwd>PROTON PUMP INHIBITION</kwd><kwd>HISTAMINE</kwd><kwd>ENTEROPATHY</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100010101</institution-id><institution>Taichung Veterans General Hospital</institution></institution-wrap></funding-source><award-id>TCVGH-1103602C, TCVGH-1103601D, TCVGH-1113602D, an</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="BX1" position="float" orientation="portrait"><sec><title>WHAT IS ALREADY KNOWN ON THIS TOPIC</title><list list-type="bullet" list-content="ul"><list-item><p>Long-term use of proton pump inhibitors (PPIs) has been associated with osteoporosis, renal dysfunction, and anaemia, although a consensus on these connections remains elusive.</p></list-item></list></sec><sec><title>WHAT THIS STUDY ADDS</title><list list-type="bullet" list-content="ul"><list-item><p>This extensive study, which involved well-matched groups of histamine-2 receptor antagonist users, revealed that the PPI group exhibited lower mean estimated glomerular filtration rate (75.74&#177;37.56 vs 78.60&#177;35.23&#8201;mL/min/1.732 m<sup>2</sup>, p&lt;0.001) and higher HR across stages 3a, 3b, 4, and 5 of chronic kidney disease.</p></list-item><list-item><p>Additionally, the PPI group had a significantly higher HR for osteoporosis (1.119) and major bone fractures (1.153), and a notably higher HR for iron deficiency anaemia (1.761).</p></list-item></list></sec><sec><title>HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY</title><list list-type="bullet" list-content="ul"><list-item><p>Healthcare providers should maintain vigilant monitoring of individuals using PPIs for extended periods to detect any potential adverse effects.</p></list-item></list></sec></boxed-text><sec sec-type="intro" id="s1"><title>Introduction</title><p> Proton pump inhibitors (PPIs) were introduced by the Food and Drug Administration in 1989 and have since accounted for 95% of prescribed acid-suppressing drugs due to their effectiveness.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> PPIs are among the most commonly prescribed medications worldwide, with their usage increasing annually.<xref rid="R2" ref-type="bibr"><sup>2</sup></xref> Over time, long-term PPI use has been associated with various adverse effects, including malabsorption in the small intestine, an increased risk of infection,<xref rid="R3" ref-type="bibr"><sup>3</sup></xref> iron deficiency anaemia (IDA),<xref rid="R4" ref-type="bibr"><sup>4</sup></xref> osteoporosis and related bone fracture,<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> renal dysfunction,<xref rid="R6" ref-type="bibr"><sup>6</sup></xref> and increased all-cause mortality.<xref rid="R7" ref-type="bibr"><sup>7 8</sup></xref></p><p>First, long-term PPI use has been reported to be linked with decreased bone mineral density (BMD), leading to osteoporosis and fractures.<xref rid="R9" ref-type="bibr"><sup>9 10</sup></xref> There are multiple hypotheses (such as decreased calcium absorption) regarding PPI-related osteoporosis,<xref rid="R11" ref-type="bibr"><sup>11</sup></xref> but not all clinical data support a causal relationship between PPIs and osteoporosis.<xref rid="R12" ref-type="bibr"><sup>12</sup></xref> This variance in findings depends on study design, including whether there are matched confounding factors or not, case numbers, duration of follow-up, and different populations (including gender, age, and geographical regions). Furthermore, the majority of published studies are case&#8211;control studies.<xref rid="R11" ref-type="bibr"><sup>11 13</sup></xref> Moreover, most studies compare PPI users with non-users, which tends to overestimate the risk of fracture due to the fact that calcium absorption is already reduced by conditions like peptic ulcer disease or gastritis in PPI users.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref> The appropriate comparison group should be histamine-2 receptor antagonist (H2RA) users, given their similar background disease conditions. H2RAs have also not been associated with osteoporosis.<xref rid="R15" ref-type="bibr"><sup>15</sup></xref> Therefore, addressing this issue requires well-matched, large-scale, and long-term follow-up studies with subgroup analysis comparing PPI and H2RA user groups.</p><p>Regarding renal dysfunction, PPIs are most commonly linked to acute interstitial nephritis (AIN),<xref rid="R16" ref-type="bibr"><sup>16</sup></xref> but only about 10% of patients exhibit the classic triad of skin rash, eosinophilia, and fever.<xref rid="R16" ref-type="bibr"><sup>16</sup></xref> Moreover, many reports of PPI-related renal dysfunction are based on postmarketing safety surveillance systems,<xref rid="R17" ref-type="bibr"><sup>17</sup></xref> which rely on voluntary reporting by physicians and consumers and are passive in nature, lacking long-term outcome data. Currently, many studies linking PPI use to chronic kidney disease (CKD) have methodological limitations due to residual confounding.<xref rid="R18" ref-type="bibr"><sup>18 19</sup></xref> Therefore, addressing this issue also necessitates well-matched, long-term follow-up studies to clarify the renal safety of PPIs.</p><p>An acidic environment is essential for iron absorption in the stomach. Therefore, the use of PPIs has been associated with decreased iron absorption,<xref rid="R20" ref-type="bibr"><sup>20</sup></xref> but mostly without clinical significance. However, in recent years, there remain cases reported on the association between PPIs and IDA.<xref rid="R21" ref-type="bibr"><sup>21 22</sup></xref> Moreover, a recent meta-analysis also showed that PPI use may still be strongly associated with the occurrence of IDA.<xref rid="R23" ref-type="bibr"><sup>23</sup></xref></p><p>Considering the aforementioned reasons, we undertook this large-scale study with well-matched groups (H2RA users) to investigate the outcomes related to kidney function, bone health, and IDA in both PPI and H2RA groups.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2-1"><title>TriNetX database</title><p>Our study leveraged data from a global collaborative network that comprises 106 prominent healthcare organisations (HCOs). Within the TriNetX network, we had access to data from more than 128&#8201;million participants spanning 15 different countries. This extensive data set provided us with the means to conduct a comprehensive analysis of various aspects of our study. The collaborative effort among these organisations was crucial in extracting valuable insights and drawing meaningful conclusions from this rich data set.</p><p>TriNetX serves as a platform that amalgamates data from electronic health records and insurance claims, creating a unified longitudinal record for each of the 11.2&#8201;million patients present in both sources. For detailed information about the validation of this data set, readers can refer to a published paper. To date, over 450 papers sourced from TriNetX have been published on PubMed.</p><p>The retrospective data set at our disposal is all-encompassing, encompassing a wide array of essential information, including demographics, diagnoses (coded using the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)), medications (coded using Anatomical Therapeutic Chemical (ATC)), laboratory tests (coded using Logical Observation Identifiers Names and Codes (LOINC)), and healthcare utilisation. The richness and diversity of this data set offer an exceptional opportunity to thoroughly explore various facets of our study with precision and depth. It is important to note that all the data used in this study were sourced from TriNetX.</p><p>The collaborative network for this research encompassed various HCOs, comprising hospitals, primary care units, and specialised medical facilities. These HCOs contributed data from both uninsured and insured patients. The primary data source for this study was the TriNetX database, which operates as a global health-focused clinical research platform. It gathers real-time electronic medical information from a network of HCOs.</p><p>To ensure the study&#8217;s rigour, we established specific criteria for inclusion and exclusion, identified the index event and index date, and delineated timeframes for the collection of baseline data. Following this, we conducted a comparative analysis of two cohorts using the integrated 1:1 propensity score matching (PSM) tool, carefully selecting the variables for matching purposes. Additionally, our methodology allowed us to define follow-up conditions, including duration, time intervals, and outcome parameters.</p></sec><sec id="s2-2"><title>Ethics statement</title><p>Due to the anonymous nature of the data, the need for obtaining informed consent was exempted. It is important to underscore that TriNetX strictly adheres to the guidelines outlined in the Health Insurance Portability and Accountability Act and the General Data Protection Regulation. All detailed database collection methods and presentations for this submission were documented according to the Strengthening the Reporting of Observational Studies in Epidemiology statement, as shown in <xref rid="SP1" ref-type="supplementary-material">online supplemental table 1</xref>.</p></sec><sec id="s2-3"><title>Patient recruitment</title><p>The recruitment algorithm is presented in <xref rid="SP1" ref-type="supplementary-material">online supplemental figure 1A</xref>. We chose the TriNetX global collaborative network first. The entire study period spans 20 years, from 23 September 2003 to 22 September 2023 for both groups. PPI or H2RA should be refilled for at least 12 times. In the PPI group, patients should not use H2RA within 20 years, and the H2RA group cannot take PPI within 20 years. Then, according to the local regulation of the institutional review board at our institute, patients should be at least 20 years old. We only included patients who were either PPI users or H2RA users without any medication shift in order to minimise the potential confounding effect of treatment changes. The final patients in both groups were then used for 1:1 PMS and then for further analysis.</p></sec><sec id="s2-4"><title>Study design</title><p>The study design for the PPI group and the H2RA group is shown in <xref rid="SP1" ref-type="supplementary-material">online supplemental figure 1B, C</xref>, respectively. For the design of the PPI group, the index event is PPI use, and the PPI use date serves as the index date. Patients in this group should not have received any H2RA throughout the study period. For the design of the H2RA group, the index event is H2RA use, and the H2RA use date is the index date. Patients in this group should not have received any PPI throughout the study period.</p><p>For both groups, baseline data were collected from 1 year to 1&#8201;day before the index date, with the most recent data also being collected. Regarding the collection of outcomes, to prevent reverse causality, we initiated data collection 1&#8201;month after the index event.</p></sec><sec id="s2-5"><title>Definition of population and outcomes</title><p>PPI was defined as ATC code A02BC, and H2RA was defined as ATC code A02BA. Every patient should have been refilled for at least 12 times. Concerning shift medication, we only included pure and new users of PPI or H2RA.</p><p>To avoid reverse causality, we started to include outcomes 1&#8201;month after the event date. We excluded patients with previous outcomes, which means our outcomes were incidence outcomes. All the desired outcomes were prespecified based on the following codes:</p><list list-type="bullet" list-content="ul"><list-item><p>Renal function: Chronic Kidney Disease Epidemiology Collaboration estimated glomerular filtration rate (CKD-EPI eGFR; LOINC codes: 98979-8). We included mean estimated glomerular filtration rate (eGFR) of 45&#8211;60&#8201;mL/min/1.732 m<sup>2</sup>, 30&#8211;45&#8201;mL/min/1.732 m<sup>2</sup>, 15&#8211;30&#8201;mL/min/1.732 m<sup>2</sup>, and &lt;15&#8201;mL/min/1.732 m<sup>2</sup>.</p></list-item><list-item><p>Anaemia outcome: iron deficiency anaemia (IDA; ICD-CM-10 D50), blood haemoglobin (g/dL; LOINC code 718-7), blood ferritin (ng/mL; LOINC code 2276-4), and blood iron (&#956;g/dL; LOINC code 2498-4).</p></list-item><list-item><p>Bone outcome: osteoporosis (ICD-CM-10 M81.0), major fracture (fracture of the spine, femur, pelvis, tibia, and arm; detailed ICD-CM-10 codes are provided in <xref rid="SP1" ref-type="supplementary-material">online supplemental table 2</xref>), blood magnesium (mg/dL; LOINC code 19123-9), blood calcium (mg/dL; LOINC code 17861-6), and blood phosphate (mg/dL; LOINC code 2777-1).</p></list-item><list-item><p>All-cause mortality: deceased code.</p></list-item></list></sec><sec id="s2-6"><title>Statistical analyses</title><p>In this study, PSM (using the built-in TriNetX tool) was employed to create matched groups with similar baseline characteristics on a 1:1 basis. The variables used for matching encompassed demographic data (age at index, sex, body mass index (BMI), and race), comorbidities (diabetes mellitus, ischaemic heart diseases, heart failure, neoplasms, osteoporosis without current pathological fracture, and nicotine dependence), blood laboratory data (haemoglobin, ferritin, iron, haemoglobin A1c, magnesium, phosphate, and low-density lipoprotein (LDL)), medications (glucocorticoids, ACE inhibitors (ACEis), angiotensin II inhibitors (ARBs), non-steroidal anti-inflammatory drugs (NSAIDs), acid, sodium-glucose cotransporter-2 inhibitors (SGLT2is), bisphosphonates, and denosumab), and renal function (CKD-EPI eGFR).</p><p>The PSM technique was seamlessly incorporated into the TriNetX system. This was achieved by employing a greedy nearest neighbour matching algorithm with a calliper set at 0.1 times the pooled SDs. In cases where the standardised mean difference (SMD) was less than 0.1, it indicated a minimal difference, demonstrating the effectiveness of the matching process.</p><p>Following this, HR was calculated along with 95%&#8201;CI to evaluate the effectiveness outcomes within both the PPI and H2RA groups. The assumption of proportional hazards was assessed using the integrated generalised Schoenfeld approach within the TriNetX platform. For continuous variables, comparisons of mean&#177;SD were conducted using Student&#8217;s t-tests.</p><p>In our Kaplan-Meier analyses, patients were subjected to censorship when they no longer contributed further information to the analysis. Censorship occurred under the following circumstances: (1) when the most recent clinical event in a patient&#8217;s record falls within the designated analysis time window, they are censored on the day immediately following the occurrence of this final event in their record; and (2) in situations where there exists a time gap between the index event and the commencement of the analysis time window, and the patient experiences the outcome after the index event but before the onset of the time window, the patient is censored at the beginning of the time window.</p><p>Subgroup analyses were conducted to investigate the variations in risk across all outcomes concerning different factors, including sex (male and female), age groups (20&#8211;&lt;64 years old vs &#8805;65 years old), and medication refill intervals (&#8805;3, 6, 12, 18, 24, and 36 months). Additionally, a sensitivity test was carried out within two collaborative networks: the US collaborative network and the Asia-Pacific collaborative network (APAC).</p></sec><sec id="s2-7"><title>Sensitivity analysis using E-values</title><p>To evaluate the robustness of our findings against potential unmeasured confounding, we calculated the E-values for the HRs of key outcomes. The E-value quantifies the minimum strength of association that an unmeasured confounder would need to have with both the exposure (PPI or H2RA use) and the outcome, on the risk ratio scale, to fully explain away the observed association.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3-1"><title>Baseline characteristics of the cohort, before and after matching</title><p>According to the recruitment algorithm (<xref rid="SP1" ref-type="supplementary-material">online supplemental figure 1A</xref>) and the study design (<xref rid="SP1" ref-type="supplementary-material">online supplemental figure 1B</xref> for the PPI group and <xref rid="SP1" ref-type="supplementary-material">online supplemental figure 1C</xref> for the H2RA group), all participants were matched in a 1:1 ratio using PSM. In <xref rid="T1" ref-type="table">table 1</xref>, before implementing PSM, PPI (n=755&#8201;794) was used significantly more than H2RA (n=126&#8201;300). After PSM, there were finally 126&#8201;155 well-matched patients in each group. In the PPI group, 18&#8201;650 patients (14.7%) were lost to follow-up, while in the H2RA group 16&#8201;135 patients (12.7%) were lost to follow-up.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><title>Baseline characteristics of study subjects before and after propensity score matching</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="bottom" colspan="1"/><th colspan="4" valign="bottom" rowspan="1">Before matching</th><th colspan="4" valign="bottom" rowspan="1">After matching</th></tr><tr><th valign="bottom" rowspan="1" colspan="1">PPI group(n=755&#8201;794)</th><th valign="bottom" rowspan="1" colspan="1">H2RA group(n=126&#8201;300)</th><th valign="bottom" rowspan="1" colspan="1">P value</th><th valign="bottom" rowspan="1" colspan="1">SMD</th><th valign="bottom" rowspan="1" colspan="1">PPI group(n=126&#8201;155)</th><th valign="bottom" rowspan="1" colspan="1">H2RA group(n=126&#8201;155)</th><th valign="bottom" rowspan="1" colspan="1">P value</th><th valign="bottom" rowspan="1" colspan="1">SMD</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Characteristics</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>n (%) or mean&#177;SD</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>n (%) or mean&#177;SD</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<bold>n (%) or mean&#177;SD</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<bold>n (%) or mean&#177;SD</bold>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Demographic data</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Age at index (years)</td><td align="left" valign="top" rowspan="1" colspan="1">63.0&#177;16.3</td><td align="left" valign="top" rowspan="1" colspan="1">58.7&#177;17.9</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.2474</td><td align="left" valign="top" rowspan="1" colspan="1">59.0&#177;17.5</td><td align="left" valign="top" rowspan="1" colspan="1">58.7&#177;17.9</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0131</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;BMI (kg/m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">28.98&#177;7.00</td><td align="left" valign="top" rowspan="1" colspan="1">28.52&#177;6.93</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0651</td><td align="left" valign="top" rowspan="1" colspan="1">28.78&#177;7.06</td><td align="left" valign="top" rowspan="1" colspan="1">28.52&#177;6.93</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0364</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Male</td><td align="left" valign="top" rowspan="1" colspan="1">371&#8201;753 (49.19)</td><td align="left" valign="top" rowspan="1" colspan="1">57&#8201;836 (45.79)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0680</td><td align="left" valign="top" rowspan="1" colspan="1">58&#8201;807 (46.62)</td><td align="left" valign="top" rowspan="1" colspan="1">57&#8201;817 (45.83)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0157</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ethnicity or race</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Black or African American</td><td align="left" valign="top" rowspan="1" colspan="1">71&#8201;930 (9.52)</td><td align="left" valign="top" rowspan="1" colspan="1">14&#8201;038 (11.12)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0525</td><td align="left" valign="top" rowspan="1" colspan="1">13&#8201;709 (10.87)</td><td align="left" valign="top" rowspan="1" colspan="1">14&#8201;012 (11.11)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0537</td><td align="left" valign="top" rowspan="1" colspan="1">0.0077</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Hispanic or Latino</td><td align="left" valign="top" rowspan="1" colspan="1">50&#8201;339 (6.66)</td><td align="left" valign="top" rowspan="1" colspan="1">9484 (7.51)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0331</td><td align="left" valign="top" rowspan="1" colspan="1">9194 (7.29)</td><td align="left" valign="top" rowspan="1" colspan="1">9465 (7.50)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0392</td><td align="left" valign="top" rowspan="1" colspan="1">0.0082</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Asian</td><td align="left" valign="top" rowspan="1" colspan="1">35&#8201;201 (4.66)</td><td align="left" valign="top" rowspan="1" colspan="1">7023 (5.56)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0410</td><td align="left" valign="top" rowspan="1" colspan="1">6176 (4.90)</td><td align="left" valign="top" rowspan="1" colspan="1">6998 (5.55)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0293</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Comorbidity</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Diabetes mellitus</td><td align="left" valign="top" rowspan="1" colspan="1">197&#8201;083 (26.08)</td><td align="left" valign="top" rowspan="1" colspan="1">30&#8201;099 (23.83)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0519</td><td align="left" valign="top" rowspan="1" colspan="1">30&#8201;524 (24.20)</td><td align="left" valign="top" rowspan="1" colspan="1">30&#8201;088 (23.85)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0422</td><td align="left" valign="top" rowspan="1" colspan="1">0.0081</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Ischaemic heart diseases</td><td align="left" valign="top" rowspan="1" colspan="1">167&#8201;827 (22.21)</td><td align="left" valign="top" rowspan="1" colspan="1">23&#8201;126 (18.31)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0970</td><td align="left" valign="top" rowspan="1" colspan="1">23&#8201;726 (18.81)</td><td align="left" valign="top" rowspan="1" colspan="1">23&#8201;122 (18.33)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0020</td><td align="left" valign="top" rowspan="1" colspan="1">0.0123</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Heart failure</td><td align="left" valign="top" rowspan="1" colspan="1">126&#8201;526 (16.74)</td><td align="left" valign="top" rowspan="1" colspan="1">14&#8201;281 (11.31)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.1570</td><td align="left" valign="top" rowspan="1" colspan="1">14&#8201;395 (11.41)</td><td align="left" valign="top" rowspan="1" colspan="1">14&#8201;280 (11.32)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4707</td><td align="left" valign="top" rowspan="1" colspan="1">0.0029</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Neoplasms</td><td align="left" valign="top" rowspan="1" colspan="1">195&#8201;106 (25.82)</td><td align="left" valign="top" rowspan="1" colspan="1">48&#8201;318 (38.26)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.2690</td><td align="left" valign="top" rowspan="1" colspan="1">49&#8201;359 (39.13)</td><td align="left" valign="top" rowspan="1" colspan="1">48&#8201;173 (38.19)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0193</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Nicotine dependence</td><td align="left" valign="top" rowspan="1" colspan="1">86&#8201;014 (11.38)</td><td align="left" valign="top" rowspan="1" colspan="1">13&#8201;648 (10.81)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0183</td><td align="left" valign="top" rowspan="1" colspan="1">13&#8201;450 (10.66)</td><td align="left" valign="top" rowspan="1" colspan="1">13&#8201;646 (10.82)</td><td align="left" valign="top" rowspan="1" colspan="1">0.2076</td><td align="left" valign="top" rowspan="1" colspan="1">0.0050</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Osteoporosis without current pathological fracture</td><td align="left" valign="top" rowspan="1" colspan="1">38&#8201;518 (5.10)</td><td align="left" valign="top" rowspan="1" colspan="1">5028 (3.98)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0536</td><td align="left" valign="top" rowspan="1" colspan="1">4890 (3.88)</td><td align="left" valign="top" rowspan="1" colspan="1">5028 (3.99)</td><td align="left" valign="top" rowspan="1" colspan="1">0.1574</td><td align="left" valign="top" rowspan="1" colspan="1">0.0056</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Laboratory data for blood</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;CKD-EPI eGFR (mL/min/1.732 m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">76.26&#177;39.303</td><td align="left" valign="top" rowspan="1" colspan="1">86.42&#177;39.97</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0.2562</td><td align="left" valign="top" rowspan="1" colspan="1">83.99&#177;42.92</td><td align="left" valign="top" rowspan="1" colspan="1">86.38&#177;39.96</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0576</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Haemoglobin (g/dL)</td><td align="left" valign="top" rowspan="1" colspan="1">11.44&#177;2.48</td><td align="left" valign="top" rowspan="1" colspan="1">11.38&#177;2.30</td><td align="left" valign="top" rowspan="1" colspan="1">0.1128</td><td align="left" valign="top" rowspan="1" colspan="1">0.0059</td><td align="left" valign="top" rowspan="1" colspan="1">11.25&#177;2.44</td><td align="left" valign="top" rowspan="1" colspan="1">11.38&#177;2.30</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0551</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Systolic blood pressure (mm Hg)</td><td align="left" valign="top" rowspan="1" colspan="1">122.7&#177;21.1</td><td align="left" valign="top" rowspan="1" colspan="1">124.0&#177;20.6</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0634</td><td align="left" valign="top" rowspan="1" colspan="1">121.7&#177;20.8</td><td align="left" valign="top" rowspan="1" colspan="1">124.0&#177;20.6</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.1128</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Magnesium (mg/dL)</td><td align="left" valign="top" rowspan="1" colspan="1">1.96&#177;0.35</td><td align="left" valign="top" rowspan="1" colspan="1">1.99&#177;0.38</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0887</td><td align="left" valign="top" rowspan="1" colspan="1">1.96&#177;0.35</td><td align="left" valign="top" rowspan="1" colspan="1">1.99&#177;0.38</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0916</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Phosphate (mg/dL)</td><td align="left" valign="top" rowspan="1" colspan="1">3.46&#177;1.09</td><td align="left" valign="top" rowspan="1" colspan="1">3.45&#177;1.01</td><td align="left" valign="top" rowspan="1" colspan="1">0.5380</td><td align="left" valign="top" rowspan="1" colspan="1">0.0031</td><td align="left" valign="top" rowspan="1" colspan="1">3.44&#177;1.06</td><td align="left" valign="top" rowspan="1" colspan="1">3.45&#177;1.01</td><td align="left" valign="top" rowspan="1" colspan="1">0.0144</td><td align="left" valign="top" rowspan="1" colspan="1">0.0155</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Haemoglobin A1c (%)</td><td align="left" valign="top" rowspan="1" colspan="1">6.55&#177;1.73</td><td align="left" valign="top" rowspan="1" colspan="1">6.65&#177;1.82</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0525</td><td align="left" valign="top" rowspan="1" colspan="1">6.56&#177;1.74</td><td align="left" valign="top" rowspan="1" colspan="1">6.65&#177;1.82</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0506</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Cholesterol in LDL (mg/dL)</td><td align="left" valign="top" rowspan="1" colspan="1">89.9&#177;39.2</td><td align="left" valign="top" rowspan="1" colspan="1">91.3&#177;38.1</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0357</td><td align="left" valign="top" rowspan="1" colspan="1">91.8&#177;39.1</td><td align="left" valign="top" rowspan="1" colspan="1">91.3&#177;38.1</td><td align="left" valign="top" rowspan="1" colspan="1">0.0842</td><td align="left" valign="top" rowspan="1" colspan="1">0.0134</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Ferritin (ng/mL)</td><td align="left" valign="top" rowspan="1" colspan="1">519.4&#177;1773.2</td><td align="left" valign="top" rowspan="1" colspan="1">667.0&#177;1546.5</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0887</td><td align="left" valign="top" rowspan="1" colspan="1">631.3&#177;2000.8</td><td align="left" valign="top" rowspan="1" colspan="1">667.0&#177;1546.8</td><td align="left" valign="top" rowspan="1" colspan="1">0.0768</td><td align="left" valign="top" rowspan="1" colspan="1">0.0200</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Iron (&#956;g/dL)</td><td align="left" valign="top" rowspan="1" colspan="1">59.4&#177;48.7</td><td align="left" valign="top" rowspan="1" colspan="1">58.6&#177;49.6</td><td align="left" valign="top" rowspan="1" colspan="1">0.0709</td><td align="left" valign="top" rowspan="1" colspan="1">0.0165</td><td align="left" valign="top" rowspan="1" colspan="1">60.7&#177;49.7</td><td align="left" valign="top" rowspan="1" colspan="1">58.6&#177;49.6</td><td align="left" valign="top" rowspan="1" colspan="1">0.0010</td><td align="left" valign="top" rowspan="1" colspan="1">0.0407</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Medication</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Glucocorticoid</td><td align="left" valign="top" rowspan="1" colspan="1">385&#8201;163 (50.96)</td><td align="left" valign="top" rowspan="1" colspan="1">78&#8201;188 (61.91)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.2221</td><td align="left" valign="top" rowspan="1" colspan="1">77&#8201;536 (61.46)</td><td align="left" valign="top" rowspan="1" colspan="1">78&#8201;044 (61.86)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0375</td><td align="left" valign="top" rowspan="1" colspan="1">0.0083</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;NSAID</td><td align="left" valign="top" rowspan="1" colspan="1">246&#8201;385 (32.60)</td><td align="left" valign="top" rowspan="1" colspan="1">42&#8201;434 (33.60)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0212</td><td align="left" valign="top" rowspan="1" colspan="1">42&#8201;025 (33.31)</td><td align="left" valign="top" rowspan="1" colspan="1">42&#8201;385 (33.60)</td><td align="left" valign="top" rowspan="1" colspan="1">0.1288</td><td align="left" valign="top" rowspan="1" colspan="1">0.0060</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;ACEi</td><td align="left" valign="top" rowspan="1" colspan="1">188&#8201;939 (25.00)</td><td align="left" valign="top" rowspan="1" colspan="1">23&#8201;475 (18.59)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.1558</td><td align="left" valign="top" rowspan="1" colspan="1">23&#8201;514 (18.64)</td><td align="left" valign="top" rowspan="1" colspan="1">23&#8201;475 (18.61)</td><td align="left" valign="top" rowspan="1" colspan="1">0.8419</td><td align="left" valign="top" rowspan="1" colspan="1">0.0008</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;ARB</td><td align="left" valign="top" rowspan="1" colspan="1">136&#8201;489 (18.06)</td><td align="left" valign="top" rowspan="1" colspan="1">19&#8201;388 (15.35)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0727</td><td align="left" valign="top" rowspan="1" colspan="1">19&#8201;257 (15.27)</td><td align="left" valign="top" rowspan="1" colspan="1">19&#8201;381 (15.36)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4930</td><td align="left" valign="top" rowspan="1" colspan="1">0.0027</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;SGLT2i</td><td align="left" valign="top" rowspan="1" colspan="1">15&#8201;020 (1.99)</td><td align="left" valign="top" rowspan="1" colspan="1">2257 (1.79)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0147</td><td align="left" valign="top" rowspan="1" colspan="1">2095 (1.66)</td><td align="left" valign="top" rowspan="1" colspan="1">2257 (1.79)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0132</td><td align="left" valign="top" rowspan="1" colspan="1">0.0099</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Bisphosphonates</td><td align="left" valign="top" rowspan="1" colspan="1">22&#8201;183 (2.94)</td><td align="left" valign="top" rowspan="1" colspan="1">3505 (2.78)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0018</td><td align="left" valign="top" rowspan="1" colspan="1">0.0096</td><td align="left" valign="top" rowspan="1" colspan="1">3251 (2.58)</td><td align="left" valign="top" rowspan="1" colspan="1">3495 (2.77)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0026</td><td align="left" valign="top" rowspan="1" colspan="1">0.0120</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Denosumab</td><td align="left" valign="top" rowspan="1" colspan="1">4288 (0.57)</td><td align="left" valign="top" rowspan="1" colspan="1">1601 (1.27)</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.0735</td><td align="left" valign="top" rowspan="1" colspan="1">1465 (1.16)</td><td align="left" valign="top" rowspan="1" colspan="1">1515 (1.20)</td><td align="left" valign="top" rowspan="1" colspan="1">0.3568</td><td align="left" valign="top" rowspan="1" colspan="1">0.0037</td></tr></tbody></table><table-wrap-foot><fn id="T1_FN1" fn-type="abbr"><p>ACEi, ACE inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CKD-EPI eGFR, Chronic Kidney Disease Epidemiology Collaboration estimated glomerular filtration rate; H2RA, histamine-2 receptor antagonist; LDL, low-density lipoprotein; NSAID, non-steroidal anti-inflammatory drug; PPI, proton pump inhibitor; SGLT2i, sodium-glucose cotransporter-2 inhibitor; SMD, standardised mean difference.</p></fn></table-wrap-foot></table-wrap><p>Overall, the patients in this cohort were relatively young, with an average age of around 59 years, and predominantly female (54%) (<xref rid="T1" ref-type="table">table 1</xref>). They had relatively fewer comorbidities, including 24% with diabetes mellitus, 18% with ischaemic heart disease, 11% with heart failure, 11% with nicotine dependence, and 4% with osteoporosis without current pathological fractures. Most of them were obese (with an average BMI of 29 kg/m<sup>2</sup>) and had good renal function (with eGFR of 84&#8211;86&#8201;mL/min/1.732 m<sup>2</sup>). Sugar control and lipid profiles were good, with haemoglobin A1c at 6.6% and LDL at 91&#8201;mg/dL. There were no underlying cases of anaemia (haemoglobin level of 11.3&#8201;g/dL), and iron profiles were within normal limits (ferritin 631&#8211;667&#8201;ng/mL and iron 59&#8211;61&#8201;&#956;g/dL). More than half of the patients had ever taken glucocorticoids (62%), but very few had received antiresorption medication for osteoporosis (2.6%&#8211;2.7% for bisphosphonates and 1% for denosumab). The PSM was well executed, as all SMDs were less than 0.1, except for systolic blood pressure, which had a tiny difference (121.7&#177;20.8 mm Hg vs 124.0&#177;20.6&#8201;mm Hg, SMD=0.1128). The PSM was well performed as shown in <xref rid="SP1" ref-type="supplementary-material">online supplemental figure 2</xref> (before PSM in <xref rid="SP1" ref-type="supplementary-material">online supplemental figure 2A</xref> and after PSM in <xref rid="SP1" ref-type="supplementary-material">online supplemental figure 2B</xref>).</p></sec><sec id="s3-2"><title>Incidence of outcomes for diagnosis and difference in laboratory outcomes between PPI and H2RA groups</title><p>The HRs for all outcomes between the PPI and H2RA groups are shown in <xref rid="T2" ref-type="table">table 2</xref>. Regarding renal function, compared with the H2RA group, the PPI group exhibited a lower mean eGFR (75.74&#177;37.56 vs 78.60&#177;35.23&#8201;mL/min/1.732 m<sup>2</sup>, p&lt;0.001). Additionally, the PPI group had a higher HR across four different eGFR ranges: 1.137 (95% CI 1.120 to 1.154), 1.260 (95% CI 1.235 to 1.286), 1.316 (95% CI 1.288 to 1.345), and 1.785 (95% CI 1.718 to 1.854) for eGFR of 45&#8211;60 mL/min/1.732&#8201;m&#178;, 30&#8211;45 mL/min/1.732&#8201;m&#178;, 15&#8211;30 mL/min/1.732&#8201;m&#178;, and &lt;15&#8201;mL/min/1.732&#8201;m&#178;, respectively. The Kaplan-Meier curves illustrating significant differences in these outcomes can be seen in <xref rid="F1" ref-type="fig">figure 1</xref> (eGFR=45&#8211;60&#8201;mL/min/1.732&#8201;m&#178; in <xref rid="F1" ref-type="fig">figure 1A</xref>, 30&#8211;45&#8201;mL/min/1.732&#8201;m&#178; in <xref rid="F1" ref-type="fig">figure 1B</xref>, 15&#8211;30&#8201;mL/min/1.732&#8201;m&#178; in <xref rid="F1" ref-type="fig">figure 1C</xref>, and &lt;15&#8201;mL/min/1.732&#8201;m&#178; in <xref rid="F1" ref-type="fig">figure 1D</xref>) (all log-rank tests p&lt;0.001).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><title>Incidence of outcomes for diagnosis and the final laboratory data in the PPI group and the H2RA group (after propensity score matching)</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="2" colspan="1"/><th valign="bottom" rowspan="1" colspan="1">Laboratory outcome</th><th colspan="4" valign="bottom" rowspan="1">Patients with outcome for diagnosis</th></tr><tr><th valign="bottom" rowspan="1" colspan="1">PPI group vs H2RA groupMean&#177;SD (p value)</th><th valign="bottom" rowspan="1" colspan="1">PPI group</th><th valign="bottom" rowspan="1" colspan="1">H2RA group</th><th valign="bottom" rowspan="1" colspan="1">HR (95%&#8201;CI)</th><th valign="bottom" rowspan="1" colspan="1">Risk difference(95%&#8201;CI)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Renal function</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;CKD-EPI eGFR (mL/min/1.732 m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">75.74&#177;37.56 vs 78.60&#177;35.23 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;eGFR=45&#8211;60 (mL/min/1.732 m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">29&#8201;419</td><td align="left" valign="top" rowspan="1" colspan="1">25&#8201;876</td><td align="left" valign="top" rowspan="1" colspan="1">1.137 (1.120 to 1.154)</td><td align="left" valign="top" rowspan="1" colspan="1">0.028 (0.025 to 0.031)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;eGFR=30&#8211;45 (mL/min/1.732 m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">18&#8201;350</td><td align="left" valign="top" rowspan="1" colspan="1">14&#8201;563</td><td align="left" valign="top" rowspan="1" colspan="1">1.260 (1.235 to 1.286)</td><td align="left" valign="top" rowspan="1" colspan="1">0.030 (0.027 to 0.033)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;eGFR=15&#8211;30 (mL/min/1.732 m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">16&#8201;777</td><td align="left" valign="top" rowspan="1" colspan="1">12&#8201;750</td><td align="left" valign="top" rowspan="1" colspan="1">1.316 (1.288 to 1.345)</td><td align="left" valign="top" rowspan="1" colspan="1">0.032 (0.029 to 0.034)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;eGFR &lt;15 (mL/min/1.732 m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">7109</td><td align="left" valign="top" rowspan="1" colspan="1">3983</td><td align="left" valign="top" rowspan="1" colspan="1">1.785 (1.718 to 1.854)</td><td align="left" valign="top" rowspan="1" colspan="1">0.025 (0.023 to 0.026)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anaemia outcome</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Iron deficiency anaemia</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">5974</td><td align="left" valign="top" rowspan="1" colspan="1">3534</td><td align="left" valign="top" rowspan="1" colspan="1">1.761 (1.691 to 1.835)</td><td align="left" valign="top" rowspan="1" colspan="1">0.023 (0.022 to 0.025)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Haemoglobin (g/dL)</td><td align="left" valign="top" rowspan="1" colspan="1">12.07&#177;2.51 vs 12.37&#177;2.28 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Ferritin (ng/mL)</td><td align="left" valign="top" rowspan="1" colspan="1">457.69&#177;2513.15 vs 504.06&#177;1806.21 (p=0.089)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Blood iron (&#956;g/dL)</td><td align="left" valign="top" rowspan="1" colspan="1">65.67&#177;44.95 vs 67.22&#177;46.14 (p=0.004)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Osteoporosis outcome</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Osteoporosis</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">4093</td><td align="left" valign="top" rowspan="1" colspan="1">3680</td><td align="left" valign="top" rowspan="1" colspan="1">1.119 (1.071 to 1.169)</td><td align="left" valign="top" rowspan="1" colspan="1">0.004 (0.002 to 0.005)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Major fracture</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">5459</td><td align="left" valign="top" rowspan="1" colspan="1">4744</td><td align="left" valign="top" rowspan="1" colspan="1">1.153 (1.110 to 1.198)</td><td align="left" valign="top" rowspan="1" colspan="1">0.007 (0.005 to 0.008)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Blood magnesium (mg/dL)</td><td align="left" valign="top" rowspan="1" colspan="1">1.94&#177;0.37 vs 1.95&#177;0.34 (p=0.001)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Blood calcium (mg/dL)</td><td align="left" valign="top" rowspan="1" colspan="1">9.10&#177;0.79 vs 9.19&#177;0.71 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Blood phosphate (mg/dL)</td><td align="left" valign="top" rowspan="1" colspan="1">3.61&#177;1.21 vs 3.53&#177;1.06 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;All-cause mortality</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">18&#8201;391</td><td align="left" valign="top" rowspan="1" colspan="1">15&#8201;541</td><td align="left" valign="top" rowspan="1" colspan="1">1.183 (1.160 to 1.207)</td><td align="left" valign="top" rowspan="1" colspan="1">0.023 (0.020 to 0.025)</td></tr></tbody></table><table-wrap-foot><fn fn-type="abbr"><p>CKD-EPI eGFR, Chronic Kidney Disease Epidemiology Collaboration estimated glomerular filtration rate; H2RA, histamine-2 receptor antagonist; PPI, proton pump inhibitor.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F1" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><title>Kaplan-Meier curves for renal outcomes. (<bold>A</bold>) eGFR=45&#8211;60 (mL/min/1.732 m<sup>2</sup>) (log-rank test p&lt;0.001); (<bold>B</bold>) eGFR=30&#8211;45 (mL/min/1.732 m<sup>2</sup>) (log-rank test p&lt;0.001); (<bold>C</bold>) eGFR=15&#8211;30 (mL/min/1.732 m<sup>2</sup>) (log-rank test p&lt;0.001); and (<bold>D</bold>) eGFR &lt;15 (mL/min/1.732 m<sup>2</sup>) (log-rank test p&lt;0.001). eGFR, estimated glomerular filtration rate; H2RA, histamine-2 receptor antagonist; PPI, proton pump inhibitor.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bmjgast-12-1-g001.jpg"/></fig><p>For the outcome of anaemia, the PPI group had a significantly higher HR (1.761, 95% CI 1.691 to 1.835) for diagnosis of IDA. This condition is also evident in the Kaplan-Meier curves for IDA (log-rank test &lt;0.001; <xref rid="F2" ref-type="fig">figure 2A</xref>). The PPI group had slightly but statistically significantly lower haemoglobin and serum iron compared with the H2RA group: 12.07&#177;2.51 g/dL vs 12.37&#177;2.28&#8201;g/dL (p&lt;0.001) for haemoglobin and 65.67&#177;44.95 &#181;g/dL vs 67.22&#177;46.14&#8201;&#181;g/dL (p=0.004) for serum iron, respectively. The PPI group also had numerically lower ferritin compared with the H2RA group, without statistical significance (457.69&#177;2513.15 ng/mL vs 504.06&#177;1806.21&#8201;ng/mL, p=0.089).</p><fig position="float" id="F2" fig-type="figure" orientation="portrait"><label>Figure 2</label><caption><title>Kaplan-Meier curves for other outcomes. (<bold>A</bold>) Iron deficiency anaemia (log-rank test p&lt;0.001); (<bold>B</bold>) osteoporosis (log-rank test p&lt;0.001); (<bold>C</bold>) major fracture (log-rank test p&lt;0.001); and (<bold>D</bold>) all-cause mortality (log-rank test p&lt;0.001). H2RA, histamine-2 receptor antagonist; PPI, proton pump inhibitor.</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bmjgast-12-1-g002.jpg"/></fig><p>Regarding the outcome of bone health, the PPI group had a higher HR for diagnosis of osteoporosis and major bone fractures: 1.119 (95% CI 1.071 to 1.169) for osteoporosis and 1.153 (95% CI 1.110 to 1.198) for major bone fractures, respectively. These differences are also evident in the Kaplan-Meier curves for osteoporosis (<xref rid="F2" ref-type="fig">figure 2B</xref>) and major bone fractures (<xref rid="F2" ref-type="fig">figure 2C</xref>) (both log-rank tests &lt;0.001). The values of serum magnesium, calcium, and phosphate were significantly lower in the PPI group: 1.94&#177;0.37 mg/dL vs 1.95&#177;0.34&#8201;mg/dL (p=0.001) for magnesium, 9.10&#177;0.79 mg/dL vs 9.19&#177;0.71&#8201;mg/dL (p&lt;0.001) for calcium, and 3.61&#177;1.21 mg/dL vs 3.53&#177;1.06 mg/dL (p&lt;0.001) for phosphate. However, these differences were very small, and the values remained within normal limits.</p><p>For all-cause mortality, there is a higher HR (1.183, 95% CI 1.160 to 1.207) for the PPI group compared with the H2RA group (<xref rid="T2" ref-type="table">table 2</xref>). This difference is also evident in the Kaplan-Meier curve for mortality (<xref rid="F2" ref-type="fig">figure 2D</xref>). The forest plots of the outcomes for the entire group are shown in <xref rid="SP1" ref-type="supplementary-material">online supplemental figure 3A</xref>.</p></sec><sec id="s3-3"><title>Subgroup analysis of gender (male and female), age (young and old), and medication refill times (&#8805;3, 6, 12, 24, and 36)</title><p>The baseline characteristics of the study subjects, both before and after PSM, are presented in <xref rid="SP1" ref-type="supplementary-material">online supplemental tables 3&#8211;11</xref> for various subgroups, including male individuals (n=57&#8201;823), female individuals (n=67&#8201;040), young individuals (n=60&#8201;123), older individuals (n=32&#8201;709), and those with medication refill times &#8805;3 (n=840&#8201;848), &#8805;6 (n=324&#8201;182), &#8805;12 (n=64&#8201;309), &#8805;24 (n=39&#8201;526), and &#8805;36 (n=18&#8201;559). The PSM yielded nearly well-matched groups (SMD &lt;0.1) in all subgroups, except for some variables. Specifically, the following disparities were observed: In the male group, the SMD value for systolic blood pressure (SBP) was 0.1161 and for magnesium 0.1151. In the female group, the SMD for SBP was 0.1211. In the young group, the SMD for SBP was 0.1160, and for iron it was 0.1074. In the older group, the SMD values were 0.1232 for SBP, 0.1135 for magnesium, and 0.1396 for ferritin. In the group with medication refill time &#8805;6, the SMD for SBP was 0.1152. In the group with medication refill time &#8805;12, the SMD for SBP was 0.163. In the group with medication refill time &#8805;24, the SMD for haemoglobin was 0.1222 and for SBP it was 0.1057. In the group with medication refill time &#8805;36, the SMD for haemoglobin was 0.1338 and for magnesium it was 0.1040.</p><p>The results of the subgroup analysis can be found in <xref rid="T3" ref-type="table">table 3</xref> and <xref rid="SP1" ref-type="supplementary-material">online supplemental figure 3</xref> (forest plots for the entire cohort in <xref rid="SP1" ref-type="supplementary-material">online supplemental figure 3A</xref>, male gender in <xref rid="SP1" ref-type="supplementary-material">online supplemental figure 3B</xref>, female gender in <xref rid="SP1" ref-type="supplementary-material">online supplemental figure 3C</xref>, young group in <xref rid="SP1" ref-type="supplementary-material">online supplemental figure 3D</xref>, old group in <xref rid="SP1" ref-type="supplementary-material">online supplemental figure 3E</xref>, medication refill time &#8805;3 in <xref rid="SP1" ref-type="supplementary-material">online supplemental figure 3F</xref>, medication refill time &#8805;6 in <xref rid="SP1" ref-type="supplementary-material">online supplemental figure 3G</xref>, medication refill time &#8805;12 in <xref rid="SP1" ref-type="supplementary-material">online supplemental figure 3H</xref>, medication refill time &#8805;24 in <xref rid="SP1" ref-type="supplementary-material">online supplemental figure 3I</xref>, and medication refill time &#8805;36 in <xref rid="SP1" ref-type="supplementary-material">online supplemental figure 3J</xref>). Across all subgroups, lower eGFR values and higher risk for different eGFR ranges were observed. Similarly, the PPI group exhibited a higher risk of IDA and lower haemoglobin values across all subgroups. The increased risk of osteoporosis and major fractures in the PPI group is also evident in all subgroup analyses, except for the young subgroup. Finally, an elevated risk of all-cause mortality in the PPI group is noticeable across all subgroups.</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><title>Incidence of outcomes for diagnosis and the final laboratory data between the PPI and H2RA groups in the subgroups of gender, age, and different medication refill times (after propensity score matching)</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" align="left" rowspan="3" colspan="1">Outcome</th><th colspan="2" valign="bottom" align="left" rowspan="1">Gender</th><th colspan="2" valign="bottom" align="left" rowspan="1">Age</th><th colspan="6" valign="bottom" align="left" rowspan="1">Medication refill times</th></tr><tr><th valign="bottom" rowspan="1" colspan="1">Male (n=57&#8201;823)</th><th valign="bottom" rowspan="1" colspan="1">Female (n=67&#8201;040)</th><th valign="bottom" rowspan="1" colspan="1">Young (n=60&#8201;123)</th><th valign="bottom" rowspan="1" colspan="1">Elderly (n=32&#8201;709)</th><th valign="bottom" rowspan="1" colspan="1">&#8805;3 (n=840&#8201;848)</th><th valign="bottom" rowspan="1" colspan="1">&#8805;6 (n=324&#8201;182)</th><th valign="bottom" rowspan="1" colspan="1">&#8805;12 (n=126&#8201;155)</th><th valign="bottom" rowspan="1" colspan="1">&#8805;12 (n=64&#8201;309)</th><th valign="bottom" rowspan="1" colspan="1">&#8805;24 (n=39&#8201;526)</th><th valign="bottom" rowspan="1" colspan="1">&#8805;36 (n=18&#8201;559)</th></tr><tr><th valign="bottom" align="left" rowspan="1" colspan="1">Mean&#177;SD or HR (95% CI)</th><th valign="bottom" rowspan="1" colspan="1">Mean&#177;SD or HR (95% CI)</th><th valign="bottom" rowspan="1" colspan="1">Mean&#177;SD or HR (95% CI)</th><th valign="bottom" rowspan="1" colspan="1">Mean&#177;SD or HR (95% CI)</th><th valign="bottom" rowspan="1" colspan="1">Mean&#177;SD or HR (95% CI)</th><th valign="bottom" rowspan="1" colspan="1">Mean&#177;SD or HR (95% CI)</th><th valign="bottom" rowspan="1" colspan="1">Mean&#177;SD or HR (95% CI)</th><th valign="bottom" rowspan="1" colspan="1">Mean&#177;SD or HR (95% CI)</th><th valign="bottom" rowspan="1" colspan="1">Mean&#177;SD or HR (95% CI)</th><th valign="bottom" rowspan="1" colspan="1">Mean&#177;SD or HR (95% CI)</th></tr></thead><tbody><tr><td colspan="11" align="left" valign="top" rowspan="1">Renal function</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;CKD-EPI eGFR (mL/min/1.732 m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">76.37&#177;39.06 vs 79.21&#177;37.13 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">74.76&#177;36.13 vs 78.03&#177;33.87 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">86.71&#177;39.35 vs 89.81&#177;35.50 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">67.73&#177;34.38 vs 70.32&#177;33.36 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">78.91&#177;33.97 vs81.89&#177;33.91 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">76.73&#177;35.73 vs 79.27&#177;34.43 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">75.74&#177;37.56 vs 78.60&#177;35.23(p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">75.06&#177;39.04 vs78.33&#177;36.45 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">75.14&#177;39.60 vs78.00&#177;37.02 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">73.71&#177;39.78 vs77.43&#177;37.84 (p&lt;0.001)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;eGFR=45&#8211;60 (mL/min/1.732 m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">1.153 (1.127 to 1.179)</td><td align="left" valign="top" rowspan="1" colspan="1">1.131 (1.109 to 1.153)</td><td align="left" valign="top" rowspan="1" colspan="1">1.232 (1.199 to 1.266)</td><td align="left" valign="top" rowspan="1" colspan="1">1.131 (1.102 to 1.161)</td><td align="left" valign="top" rowspan="1" colspan="1">1.184 (1.176 to 1.192)</td><td align="left" valign="top" rowspan="1" colspan="1">1.135 (1.125 to 1.146)</td><td align="left" valign="top" rowspan="1" colspan="1">1.137 (1.120 to 1.154)</td><td align="left" valign="top" rowspan="1" colspan="1">1.133 (1.110 to 1.156)</td><td align="left" valign="top" rowspan="1" colspan="1">1.132 (1.104 to 1.162)</td><td align="left" valign="top" rowspan="1" colspan="1">1.129 (1.089 to 1.172)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;eGFR=30&#8211;45 (mL/min/1.732 m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">1.266 (1.228 to 1.306)</td><td align="left" valign="top" rowspan="1" colspan="1">1.258 (1.224 to 1.292)</td><td align="left" valign="top" rowspan="1" colspan="1">1.466 (1.407 to 1.527)</td><td align="left" valign="top" rowspan="1" colspan="1">1.227 (1.186 to 1.270)</td><td align="left" valign="top" rowspan="1" colspan="1">1.275 (1.264 to 1.287)</td><td align="left" valign="top" rowspan="1" colspan="1">1.225 (1.209 to 1.241)</td><td align="left" valign="top" rowspan="1" colspan="1">1.260 (1.235 to 1.286)</td><td align="left" valign="top" rowspan="1" colspan="1">1.277 (1.243 to 1.313)</td><td align="left" valign="top" rowspan="1" colspan="1">1.132 (1.104 to 1.162)</td><td align="left" valign="top" rowspan="1" colspan="1">1.260 (1.200 to 1.323)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;eGFR=15&#8211;30 (mL/min/1.732 m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">1.343 (1.300 to 1.387)</td><td align="left" valign="top" rowspan="1" colspan="1">1.309 (1.272 to 1.349)</td><td align="left" valign="top" rowspan="1" colspan="1">1.570&#8201;(1.504 to 1.639)</td><td align="left" valign="top" rowspan="1" colspan="1">1.275 (1.229 to 1.323)</td><td align="left" valign="top" rowspan="1" colspan="1">1.320 (1.307 to 1.333)</td><td align="left" valign="top" rowspan="1" colspan="1">1.276 (1.258 to 1.294)</td><td align="left" valign="top" rowspan="1" colspan="1">1.316 (1.288 to 1.345)</td><td align="left" valign="top" rowspan="1" colspan="1">1.344 (1.305 to 1.384)</td><td align="left" valign="top" rowspan="1" colspan="1">1.341 (1.293 to 1.391)</td><td align="left" valign="top" rowspan="1" colspan="1">1.354 (1.285 to 1.426)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;eGFR &lt;15 (mL/min/1.732 m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">1.857 (1.757 to 1.962)</td><td align="left" valign="top" rowspan="1" colspan="1">1.735 (1.646 to 1.829)</td><td align="left" valign="top" rowspan="1" colspan="1">2.091 (1.967 to 2.223)</td><td align="left" valign="top" rowspan="1" colspan="1">1.599 (1.491 to 1.715)</td><td align="left" valign="top" rowspan="1" colspan="1">1.782 (1.754 to 1.811)</td><td align="left" valign="top" rowspan="1" colspan="1">1.751 (1.709 to 1.794)</td><td align="left" valign="top" rowspan="1" colspan="1">1.785 (1.718 to 1.854)</td><td align="left" valign="top" rowspan="1" colspan="1">1.190 (1.119 to 1.265)</td><td align="left" valign="top" rowspan="1" colspan="1">1.801 (1.688 to 1.922)</td><td align="left" valign="top" rowspan="1" colspan="1">1.925 (1.754 to 2.113)</td></tr><tr><td colspan="11" align="left" valign="top" rowspan="1">Anaemia outcome</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Iron deficiency anaemia</td><td align="left" valign="top" rowspan="1" colspan="1">1.849 (1.732 to 1.973)</td><td align="left" valign="top" rowspan="1" colspan="1">1.671 (1.584 to 1.762)</td><td align="left" valign="top" rowspan="1" colspan="1">1.601 (1.506 to 1.702)</td><td align="left" valign="top" rowspan="1" colspan="1">1.874 (1.730 to 2.030)</td><td align="left" valign="top" rowspan="1" colspan="1">1.817 (1.787 to 1.847)</td><td align="left" valign="top" rowspan="1" colspan="1">1.745 (1.701 to 1.790)</td><td align="left" valign="top" rowspan="1" colspan="1">1.761 (1.691 to 1.835)</td><td align="left" valign="top" rowspan="1" colspan="1">1.778 (1.681 to 1.880)</td><td align="left" valign="top" rowspan="1" colspan="1">1.682 (1.566 to 1.806)</td><td align="left" valign="top" rowspan="1" colspan="1">1.897 (1.715 to 2.097)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Haemoglobin (g/dL)</td><td align="left" valign="top" rowspan="1" colspan="1">12.37&#177;2.74 vs12.77&#177;2.54 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">11.79&#177;2.24 vs12.06&#177;2.01 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">12.41&#177;2.57 vs 12.75&#177;2.22 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">11.99&#177;2.61 vs12.30&#177;2.49 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">12.50&#177;2.33 vs 12.65&#177;2.18 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">12.27&#177;2.44 vs12.50&#177;2.24 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">12.07&#177;2.51 vs 12.37&#177;2.28 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">11.97&#177;2.55 vs12.29&#177;2.34 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">11.95&#177;2.58&#8201;vs12.28&#177;2.36 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">11.91&#177;2.57 vs 12.27&#177;2.38 (p&lt;0.001)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Ferritin (ng/mL)</td><td align="left" valign="top" rowspan="1" colspan="1">512.53&#177;3026.63 vs652.51&#177;2092.81 (p=0.006)</td><td align="left" valign="top" rowspan="1" colspan="1">392.06&#177;1916.73 vs405.42&#177;1597.74 (p=0.644)</td><td align="left" valign="top" rowspan="1" colspan="1">492.65&#177;2531.19 vs 464.79&#177;1696.77 (p=0.475)</td><td align="left" valign="top" rowspan="1" colspan="1">501.40&#177;1708.33 vs642.50&#177;1879.27 (p=0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">327.58&#177;2376.52 vs 345.38&#177;1386.74 (p=0.079)</td><td align="left" valign="top" rowspan="1" colspan="1">403.78&#177;2269.82 vs419.02&#177;1449.25 (p=0.312)</td><td align="left" valign="top" rowspan="1" colspan="1">457.69&#177;2513.15 vs 504.06&#177;1806.21 (p=0.089)</td><td align="left" valign="top" rowspan="1" colspan="1">495.04&#177;1963.52 vs579.30&#177;2128.46 (p=0.013)</td><td align="left" valign="top" rowspan="1" colspan="1">555.27&#177;2641.79 vs628.22&#177;2396.96 (p=0.178)</td><td align="left" valign="top" rowspan="1" colspan="1">643.30&#177;4814.13 vs 739.10&#177;3198.80 (p=0.463)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Blood iron (&#956;g/dL)</td><td align="left" valign="top" rowspan="1" colspan="1">66.18&#177;46.73 vs68.14&#177;49.03 (p=0.029)</td><td align="left" valign="top" rowspan="1" colspan="1">65.79&#177;45.06 vs66.35&#177;44.36 (p=0.425)</td><td align="left" valign="top" rowspan="1" colspan="1">70.54&#177;48.24 vs 70.43&#177;48.15 (p=0.889)</td><td align="left" valign="top" rowspan="1" colspan="1">63.14&#177;43.80 vs 65.37&#177;46.56 (p=0.039)</td><td align="left" valign="top" rowspan="1" colspan="1">68.00&#177;44.95 vs 68.58&#177;43.04 (p=0.006)</td><td align="left" valign="top" rowspan="1" colspan="1">66.59&#177;45.04 vs 67.64&#177;44.11 (p=0.002)</td><td align="left" valign="top" rowspan="1" colspan="1">65.67&#177;44.95 vs 67.22&#177;46.14 (p=0.004)</td><td align="left" valign="top" rowspan="1" colspan="1">66.02&#177;45.85 vs 67.80&#177;49.18 (p=0.022)</td><td align="left" valign="top" rowspan="1" colspan="1">66.63&#177;48.32 vs 68.25&#177;47.82 (p=0.111)</td><td align="left" valign="top" rowspan="1" colspan="1">68.06&#177;51.00 vs 69.09&#177;49.71 (p=0.499)</td></tr><tr><td colspan="11" align="left" valign="top" rowspan="1">Osteoporosis outcome</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Osteoporosis</td><td align="left" valign="top" rowspan="1" colspan="1">1.121 (1.024 to 1.229)</td><td align="left" valign="top" rowspan="1" colspan="1">1.120 (1.065 to 1.177)</td><td align="left" valign="top" rowspan="1" colspan="1">0.994 (0.916 to 1.079)</td><td align="left" valign="top" rowspan="1" colspan="1">1.269 (1.140 to 1.413)</td><td align="left" valign="top" rowspan="1" colspan="1">1.288 (1.263 to 1.313)</td><td align="left" valign="top" rowspan="1" colspan="1">1.185 (1.152 to 1.219)</td><td align="left" valign="top" rowspan="1" colspan="1">1.119 (1.071 to 1.169)</td><td align="left" valign="top" rowspan="1" colspan="1">1.190 (1.119 to 1.265)</td><td align="left" valign="top" rowspan="1" colspan="1">1.246 (1.155 to 1.344)</td><td align="left" valign="top" rowspan="1" colspan="1">1.223 (1.102 to 1.357)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Major fracture</td><td align="left" valign="top" rowspan="1" colspan="1">1.181 (1.103 to 1.264)</td><td align="left" valign="top" rowspan="1" colspan="1">1.178 (1.126 to 1.234)</td><td align="left" valign="top" rowspan="1" colspan="1">1.049 (0.980 to 1.122)</td><td align="left" valign="top" rowspan="1" colspan="1">1.224 (1.126 to 1.330)</td><td align="left" valign="top" rowspan="1" colspan="1">1.297 (1.276 to 1.318)</td><td align="left" valign="top" rowspan="1" colspan="1">1.201 (1.172 to 1.231)</td><td align="left" valign="top" rowspan="1" colspan="1">1.153 (1.110 to 1.198)</td><td align="left" valign="top" rowspan="1" colspan="1">1.175 (1.114 to 1.239)</td><td align="left" valign="top" rowspan="1" colspan="1">1.187 (1.111 to 1.268)</td><td align="left" valign="top" rowspan="1" colspan="1">1.220 (1.113 to 1.337)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Blood magnesium (mg/dL)</td><td align="left" valign="top" rowspan="1" colspan="1">1.95&#177;0.38 vs1.96&#177;0.32 (p=0.013)</td><td align="left" valign="top" rowspan="1" colspan="1">1.94&#177;0.38 vs 1.94&#177;0.36 (p=0.684)</td><td align="left" valign="top" rowspan="1" colspan="1">1.93&#177;0.38 vs 1.94&#177;0.35 (p=0.018)</td><td align="left" valign="top" rowspan="1" colspan="1">1.96&#177;0.36 vs 1.98&#177;0.32 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">1.94&#177;0.36 vs 1.96&#177;0.38 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">1.94&#177;0.36 vs 1.95&#177;0.35 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">1.94&#177;0.37 vs 1.95&#177;0.34 (p=0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">1.94&#177;0.38 vs1.95&#177;0.34 (p=0.024)</td><td align="left" valign="top" rowspan="1" colspan="1">1.95&#177;0.35 vs1.96&#177;0.34 (p=0.030)</td><td align="left" valign="top" rowspan="1" colspan="1">1.95&#177;0.35 vs 1.96&#177;0.33 (p=0.020)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Blood calcium (mg/dL)</td><td align="left" valign="top" rowspan="1" colspan="1">9.05&#177;0.80 vs 9.13&#177;0.71 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">9.13&#177;0.79 vs 9.23&#177;0.70 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">9.13&#177;0.76 vs 9.24&#177;0.66 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">8.98&#177;0.80 vs9.06&#177;0.0.73 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">9.19&#177;0.71 vs 9.22&#177;0.68 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">9.14&#177;0.75 vs 9.21&#177;0.70 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">9.10&#177;0.79 vs 9.19&#177;0.71 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">9.07&#177;0.79 vs9.15&#177;0.71 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">9.03&#177;0.82 vs9.14&#177;0.71 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">9.02&#177;0.81 vs9.13&#177;0.70 (p&lt;0.001)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;Blood phosphate (mg/dL)</td><td align="left" valign="top" rowspan="1" colspan="1">3.60&#177;1.34 vs3.52&#177;1.10 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">3.62&#177;1.19 vs 3.53&#177;1.03 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">3.72&#177;1.30 vs 3.60&#177;1.07 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">3.51&#177;1.19 vs 3.46&#177;1.10 (p=0.007)</td><td align="left" valign="top" rowspan="1" colspan="1">3.58&#177;1.19&#8201;vs.3.52&#177;1.05 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">3.59&#177;1.20 vs 3.52&#177;1.08 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">3.61&#177;1.21 vs 3.53&#177;1.06 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">3.62&#177;1.22&#8201;vs3.53&#177;1.06 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">3.64&#177;1.24 vs 3.54&#177;1.07 (p&lt;0.001)</td><td align="left" valign="top" rowspan="1" colspan="1">3.64&#177;1.53 vs 3.54&#177;1.08 (p&lt;0.001)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#8195;All-cause mortality</td><td align="left" valign="top" rowspan="1" colspan="1">1.176 (1.144 to 1.209)</td><td align="left" valign="top" rowspan="1" colspan="1">1.194 (1.161 to 1.228)</td><td align="left" valign="top" rowspan="1" colspan="1">1.383 (1.330 to 1.438)</td><td align="left" valign="top" rowspan="1" colspan="1">1.106 (1.071 to 1.141)</td><td align="left" valign="top" rowspan="1" colspan="1">1.208 (1.195 to 1.220)</td><td align="left" valign="top" rowspan="1" colspan="1">1.167 (1.152 to 1.183)</td><td align="left" valign="top" rowspan="1" colspan="1">1.183 (1.160 to 1.207)</td><td align="left" valign="top" rowspan="1" colspan="1">1.132 (1.102 to 1.162)</td><td align="left" valign="top" rowspan="1" colspan="1">1.147 (1.110 to 1.185)</td><td align="left" valign="top" rowspan="1" colspan="1">1.156 (1.105 to 1.210)</td></tr></tbody></table><table-wrap-foot><fn fn-type="abbr"><p>CKD-EPI eGFR, Chronic Kidney Disease Epidemiology Collaboration estimated glomerular filtration rate; H2RA, histamine-2 receptor antagonist; PPI, proton pump inhibitor.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-4"><title>Sensitivity test in the US and APAC collaborative networks</title><p>The baseline characteristics of the study subjects, both before and after PSM, in the US collaborative network (n=102&#8201;453) and the APAC collaborative network (n=12&#8201;066) are presented in <xref rid="SP1" ref-type="supplementary-material">online supplemental tables 12 and 13</xref>, respectively. After PSM, there were no noticeable differences between the PPI and H2RA groups, except for the following variations: SMD of 0.1036 for magnesium in the US collaborative network, SMD of 0.1881 for haemoglobin in the APAC collaborative network, SMD of 0.2419 for glomerular filtration rate in the APAC collaborative network, and SMD of 0.1117 for haemoglobin A1c in the APAC collaborative network.</p><p>The outcomes of the sensitivity test are shown in <xref rid="SP1" ref-type="supplementary-material">online supplemental table 14</xref> and <xref rid="SP1" ref-type="supplementary-material">online supplemental figure 4A</xref> for US and <xref rid="SP1" ref-type="supplementary-material">online supplemental figure 4B</xref> for APAC collaborative networks. Lower renal function in the PPI group is evident in both the US and APAC populations, including the mean eGFR (77.20&#177;38.07 vs 79.60&#177;35.49&#8201;mL/min/1.732 m<sup>2</sup> (p&lt;0.001) in the US population and 61.59&#177;32.91 vs 70.34&#177;32.95&#8201;mL/min/1.732 m<sup>2</sup> (p&lt;0.001) in the APAC population), as well as in four ranges of eGFR. Furthermore, a higher HR for IDA in the PPI group can be observed in both the US and APAC populations (1.738 (95% CI 1.665 to 1.814) and 3.226 (95% CI 2.774 to 3.751), respectively).</p><p>Additionally, the PPI groups in both the US and APAC populations exhibited lower haemoglobin levels (12.10&#177;2.41 g/dL vs 12.34&#177;2.27&#8201;g/dL (p&lt;0.001) for the US population and 12.27&#177;2.31 g/dL vs 12.65&#177;2.21&#8201;g/dL (p&lt;0.001) for the APAC population) and lower ferritin values (451.53&#177;1854.48 ng/mL vs 504.09&#177;1822.31&#8201;ng/mL (p=0.024) for the US population and 401.79&#177;790.12 ng/mL vs 586.33&#177;1686.37&#8201;ng/mL (p=0.003) for the APAC population). Moreover, there were more diagnoses of osteoporosis in the PPI group compared with the H2RA group in both the US and APAC populations (1.114 (95% CI 1.063 to 1.166) and 1.589 (95% CI 1.349 to 1.871), respectively).</p><p>As for major bone fractures, a higher risk for the PPI group can be observed in the US population (1.732, 95% CI 1.661 to 1.805), but not in the APAC population. Lastly, the PPI group had a higher risk of mortality (1.085, 95% CI 1.065 to 1.106 and 1.891, 95% CI 1.715 to 2.085) in both the US and APAC populations.</p><p>The sensitivity analysis using E-values is shown in <xref rid="T4" ref-type="table">table 4</xref>. For example, the observed HR for eGFR &lt;15&#8201;mL/min/1.732&#8201;m&#178; was 1.785, corresponding to an E-value of 3.04 (2.92 for the lower confidence limit). Similarly, the association between PPI use and IDA yielded an E-value of 2.98 (2.86 for the lower limit). These values suggest that a relatively strong unmeasured confounder would be necessary to negate these associations, reinforcing the robustness of our results. For other outcomes, such as all-cause mortality (HR 1.183), the E-value was 1.66, indicating moderate sensitivity to unmeasured confounding. Overall, these findings support the internal validity of the observed associations in our propensity score-matched cohort.</p><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4</label><caption><title>Sensitivity analysis using E-values</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="1" colspan="1">Outcome</th><th valign="bottom" rowspan="1" colspan="1">HR (95%&#8201;CI)</th><th valign="bottom" rowspan="1" colspan="1">E-value (for point estimate)</th><th valign="bottom" rowspan="1" colspan="1">E-value (for lower CI)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">eGFR &lt;15</td><td align="left" valign="top" rowspan="1" colspan="1">1.785 (1.718 to 1.854)</td><td align="left" valign="top" rowspan="1" colspan="1">3.04</td><td align="left" valign="top" rowspan="1" colspan="1">2.92</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Iron deficiency anaemia</td><td align="left" valign="top" rowspan="1" colspan="1">1.761 (1.691 to 1.835)</td><td align="left" valign="top" rowspan="1" colspan="1">2.98</td><td align="left" valign="top" rowspan="1" colspan="1">2.86</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">eGFR 15&#8211;30</td><td align="left" valign="top" rowspan="1" colspan="1">1.316 (1.288 to 1.345)</td><td align="left" valign="top" rowspan="1" colspan="1">1.99</td><td align="left" valign="top" rowspan="1" colspan="1">1.93</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Osteoporosis</td><td align="left" valign="top" rowspan="1" colspan="1">1.119 (1.071 to 1.169)</td><td align="left" valign="top" rowspan="1" colspan="1">1.52</td><td align="left" valign="top" rowspan="1" colspan="1">1.42</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Major fracture</td><td align="left" valign="top" rowspan="1" colspan="1">1.153 (1.110 to 1.198)</td><td align="left" valign="top" rowspan="1" colspan="1">1.60</td><td align="left" valign="top" rowspan="1" colspan="1">1.50</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">All-cause mortality</td><td align="left" valign="top" rowspan="1" colspan="1">1.183 (1.160 to 1.207)</td><td align="left" valign="top" rowspan="1" colspan="1">1.66</td><td align="left" valign="top" rowspan="1" colspan="1">1.61</td></tr></tbody></table><table-wrap-foot><fn fn-type="abbr"><p>eGFR, estimated glomerular filtration rate.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>This is a comprehensive, well-matched, large-scale, long-term follow-up study aimed at evaluating the impact of PPI versus H2RA use on renal function, bone health, and IDA. In this study, we meticulously controlled for numerous potential confounding variables across different outcomes, including demographics, socioeconomic status, clinical measurements, prevalent comorbidities, and concurrent medication use. Notably, we exclusively included individuals who consistently used either PPIs or H2RAs throughout the study period to minimise bias associated with medication switching. Our results revealed that PPI use (compared with H2RA use) is associated with adverse effects on eGFR, IDA, bone health (osteoporosis and major bone fracture), and overall mortality. These findings remained consistent across all subgroups, including different genders, age groups, and medication refill patterns. Furthermore, our sensitivity analyses confirmed these conclusions across various geographical regions, encompassing both the US and the APAC collaborative networks.</p><p>In our study, the PPI group exhibited lower eGFR values during follow-up and a higher probability of progressing to CKD stages 3, 4, and 5. These findings were remarkably consistent across all subgroups and geographical regions. Our findings align with previous cohort studies.<xref rid="R18" ref-type="bibr"><sup>18 24</sup></xref> In 2016, the first large-scale cohort study, involving 173&#8201;321 participants, was conducted using the Department of Veterans Affairs national databases (Veterans Affairs Saint Louis Health Care System).<xref rid="R19" ref-type="bibr"><sup>19</sup></xref> This study revealed a heightened risk of CKD among PPI users, as determined through 1:1 PSM and adjusted Cox models. However, it is worth noting that this study did not account for essential medications related to renal function in their matching process, such as ACEis, ARBs, SGLT2is, and NSAIDs, leading to potential confounding by medication. In the same year, another significant cohort study was conducted in the USA, using data from the Geisinger Health System, a regional healthcare provider serving central, south-central, and northeastern Pennsylvania, as well as various US communities.<xref rid="R25" ref-type="bibr"><sup>25</sup></xref> This study considered medications as adjusted or matched factors. Nevertheless, the study&#8217;s population was derived from the Atherosclerosis Risk in Communities,<xref rid="R26" ref-type="bibr"><sup>26</sup></xref> which had few prevalent PPI users at baseline, potentially causing selection bias. The results indicated an association between PPI use and CKD in all analyses (adjusted HR 1.24, 95%&#8201;CI 1.20 to 1.28), with similar outcomes observed in PSM (HR 1.76, 95%&#8201;CI 1.13 to 2.74). Beyond USA-based cohorts, a study conducted in the Stockholm region from 2007 to 2010, part of the North European healthcare system, revealed an increased risk of CKD among PPI users following 1:1 PSM and Cox regression analysis.<xref rid="R18" ref-type="bibr"><sup>18</sup></xref> Notably, our study is the first cohort to include Asian populations within the APAC collaborative network. Therefore, the adverse renal outcomes associated with PPI use, compared with H2RA, are no longer limited to Western countries or white populations but are also evident among Asians, as demonstrated by our findings. Furthermore, CKD in our study was diagnosed based on final eGFR measurements rather than diagnostic codes, providing greater precision than relying solely on ICD reporting. In summary, our study encompasses a broader population and offers a more accurate diagnosis of CKD in evaluating the risks of PPI versus H2RA use.</p><p>In previous studies,<xref rid="R18" ref-type="bibr"><sup>18 19</sup></xref> a graded association was observed between cumulative PPI exposure and the risk of CKD progression. However, it is worth noting that this increased risk appeared to diminish after 720 days of exposure, possibly due to survivorship bias.<xref rid="R19" ref-type="bibr"><sup>19 27</sup></xref> In our study, we did not observe a dose-dependent relationship (the subgroups of medication refill times), which could be attributed to differences in our study design. Specifically, medication refill times in our study were not consistently continuous prescriptions and usage. Another possibility is that PPI-related renal injury may primarily result from AIN. It is important to note that nearly 30%&#8211;70% of patients with AIN do not experience full recovery of renal function,<xref rid="R6" ref-type="bibr"><sup>6 28</sup></xref> leading to the development of CKD later on. Furthermore, PPI-related AIN does not appear to exhibit a dose-dependent relationship.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref></p><p>In our study, we found that PPI users had a higher risk of developing osteoporosis and experiencing major bone fractures across all groups, except for the younger group, which did not show an increased risk for either condition. Similarly, the APAC group did not exhibit an elevated risk of major fractures. This increased risk may be attributed to PPI-induced hypochlorhydria, which can enhance osteoclastic activity and consequently lead to reduced bone density.<xref rid="R29" ref-type="bibr"><sup>29</sup></xref> The current literature consists of 16 case&#8211;control studies,<xref rid="R30" ref-type="bibr">30</xref><xref rid="R33" ref-type="bibr">33</xref> which suffer from recall and sampling biases, along with only one PSM cohort study<xref rid="R34" ref-type="bibr"><sup>34</sup></xref> based on a UK database spanning from 2000 to 2016. Many of these studies failed to adequately adjust for baseline conditions,<xref rid="R14" ref-type="bibr">1431</xref><xref rid="R40" ref-type="bibr">40</xref> especially major confounding factors associated with osteoporosis, such as medication (eg, glucocorticoids) and BMI. Several studies<xref rid="R41" ref-type="bibr"><sup>41 42</sup></xref> relied on self-reported fractures, introducing potential recall bias, and one study even included traumatic fractures as part of their outcome.<xref rid="R43" ref-type="bibr"><sup>43</sup></xref> Despite the heterogeneity among these studies, almost all reports supported the association between PPI use and bone fractures.<xref rid="R30" ref-type="bibr"><sup>30</sup></xref> However, some studies did not find a positive link between PPI use and bone fractures,<xref rid="R32" ref-type="bibr"><sup>32 39</sup></xref> which may be due to shorter durations of PPI exposure,<xref rid="R32" ref-type="bibr"><sup>32</sup></xref> information bias in case&#8211;control studies,<xref rid="R44" ref-type="bibr"><sup>44</sup></xref> relatively limited case numbers,<xref rid="R39" ref-type="bibr"><sup>39</sup></xref> or the absence of longitudinal follow-up in cross-sectional studies.<xref rid="R45" ref-type="bibr"><sup>45</sup></xref> In our study, we carefully matched factors associated with osteoporosis, including baseline osteoporosis diagnosis, smoking status, BMI, renal function, and medication use (eg, glucocorticoids, bisphosphonates, and denosumab). Our outcomes relied on diagnostic codes for both osteoporosis and bone fractures, rather than self-reported data. As a result, we offer new and more robust evidence regarding the association between PPI use and the risk of osteoporosis and fractures.</p><p>The APAC group did not exhibit an elevated risk of major fractures. Cultural, dietary, physical activity,<xref rid="R46" ref-type="bibr"><sup>46</sup></xref> and healthcare practice differences may contribute to the observed lower fracture risk in younger populations and the APAC region. For instance, traditional diets in many APAC countries include calcium-rich and vitamin D-rich foods such as fish, soy products, and fortified items, which are associated with improved bone health.<xref rid="R47" ref-type="bibr"><sup>47 48</sup></xref> Physical activity patterns, including routine walking and cycling, are prevalent in several APAC countries and have been linked to better BMD.<xref rid="R46" ref-type="bibr"><sup>46 49</sup></xref> Additionally, exposure to sunlight, which facilitates vitamin D synthesis, is more common in certain regions, further enhancing bone health.<xref rid="R50" ref-type="bibr"><sup>50</sup></xref> Healthcare practices also vary significantly across the APAC region. Many countries have implemented public health initiatives focusing on osteoporosis prevention, such as early screening and treatment programme. For example, Taiwan has developed a comprehensive fracture liaison service network to improve postfracture care and prevent secondary fractures.<xref rid="R51" ref-type="bibr"><sup>51</sup></xref> Furthermore, cultural norms emphasising intergenerational living arrangements<xref rid="R52" ref-type="bibr"><sup>52 53</sup></xref> may encourage younger individuals to adopt healthier lifestyle habits, guided by family elders, which could have a protective effect on bone health. Collectively, these factors suggest that the observed differences in fracture risk may not solely reflect biological or pharmacological variables but rather an interplay of cultural, dietary, and healthcare system influences specific to certain APAC populations.</p><p>PPI-related IDA has been reported in certain observational studies.<xref rid="R54" ref-type="bibr"><sup>54</sup></xref> In our study, we have also presented evidence linking PPI use to a higher incidence of IDA. To our knowledge, this is the largest cohort study to establish this association. The increased diagnosis of IDA was consistently observed across all subgroup analyses and geographical regions. Even small but statistically significant reductions in haemoglobin levels in the PPI group were detected in our study. The possible mechanism behind this phenomenon has been reported as reduced gastric acidity, which leads to lower iron absorption.</p><p>This study has several limitations. First, the associations observed in this study do not permit us to draw conclusions about causality. Despite the use of PSM to minimise confounding, residual confounding remains a possibility, particularly due to the lack of data on important lifestyle-related factors or baseline conditions. Variables such as dietary intake, alcohol consumption, smoking status, and physical activity were not available in our data set and therefore could not be adjusted for. These factors are well recognised to influence the development and progression of CKD, bone mineral loss, and iron metabolism, and may differ systematically between patients prescribed PPIs versus H2RAs. For instance, individuals with poor nutritional habits may be more likely to experience anaemia or osteoporosis, and also more likely to receive acid-suppressive therapy due to gastrointestinal symptoms. While the E-value analysis suggests that a strong unmeasured confounder would be required to fully explain away some of the observed associations (eg, for eGFR &lt;15&#8201;or IDA), we cannot entirely exclude the influence of such unmeasured lifestyle factors. However, as TriNetX does not capture every potential confounder (lifestyle factors and all baseline diagnoses), we have acknowledged this limitation in the manuscript. Future studies incorporating detailed patient-reported lifestyle data or biomarker proxies may help further clarify these associations. Second, while we recognise that certain nuanced clinical factors (eg, symptom severity of dyspepsia, presence of gastrointestinal bleeding, or physician prescribing preferences) may not be fully captured in electronic medical record-based variables, the covariates used in our matching strategy were selected to approximate overall disease burden and treatment eligibility as closely as possible. Third, concerning renal outcomes, we lacked urinary data on proteinuria and haematuria to clarify the results of urinary analysis. Fourth, the exposure to PPIs and H2RAs was determined based on prescription data without evaluating adherence. Although prescription refills were used to define medication exposure, adherence measures such as medication possession ratio or proportion of days covered were not available in the database. Therefore, actual patient adherence could not be confirmed, and this may introduce exposure misclassification. Lastly, we did not have sufficient BMD data to directly assess bone health. Although serum magnesium, calcium, and phosphate levels were significantly lower in the PPI group, these differences were minimal and still within normal limits. Given this limitation, future research should include additional osteoporosis markers for a more comprehensive evaluation.</p></sec><sec sec-type="conclusions" id="s5"><title>Conclusion</title><p>In the large TriNetX matched cohort study, PPI users were found to have a higher risk of developing CKD, osteoporosis, major bone fractures, IDA, and increased mortality. Although a definite causal effect has not been established, we still believe that clinicians should pay close attention to the long-term use of PPIs and monitor for the aforementioned adverse effects. Once long-term use of these treatments is established, we suggest regular follow-up of renal function, IDA, and bone density, as such monitoring may be helpful in identifying potential adverse outcomes.</p></sec><sec sec-type="supplementary-material" id="s6"><title>Supplementary material</title><supplementary-material id="SP1" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1136/bmjgast-2024-001723</object-id><label>online supplemental file 1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bmjgast-12-1-s001.docx" id="d67e2042" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> This study was supported by grants TCVGH-1103602C, TCVGH-1103601D, TCVGH-1113602D, and TCVGH-1123603C from Taichung Veterans General Hospital.</p></fn><fn fn-type="other"><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn><fn fn-type="other"><p><bold>Patient consent for publication:</bold> Not required.</p></fn><fn fn-type="other"><p><bold>Data availability free text:</bold> The data that support the findings of this study are available from TriNetX, but restrictions apply to the availability of these data, which were used under licence for the current study. Researchers may apply for access to the data by contacting TriNetX.</p></fn><fn fn-type="other"><p><bold>Ethics approval:</bold> The Western Institutional Review Board (IRB) has granted TriNetX an exemption from requiring informed consent as the platform exclusively compiles aggregate counts and statistical summaries of de-identified data. Furthermore, our specific utilisation of the TriNetX platform for this research study has received approval from the IRB committee of Taichung Veterans General Hospital (approval number SE22220A-1).</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strid</surname><given-names>H</given-names></name><name name-style="western"><surname>Simr&#233;n</surname><given-names>M</given-names></name><name name-style="western"><surname>Bj&#246;rnsson</surname><given-names>ES</given-names></name></person-group><article-title>Overuse of acid suppressant drugs in patients with chronic renal failure</article-title><source>Nephrol Dial Transplant</source><year>2003</year><volume>18</volume><fpage>570</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1093/ndt/18.3.570</pub-id><pub-id pub-id-type="pmid">12584281</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forgacs</surname><given-names>I</given-names></name><name name-style="western"><surname>Loganayagam</surname><given-names>A</given-names></name></person-group><article-title>Overprescribing proton pump inhibitors</article-title><source><italic toggle="yes">BMJ</italic></source><year>2008</year><volume>336</volume><fpage>2</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1136/bmj.39406.449456.BE</pub-id><pub-id pub-id-type="pmid">18174564</pub-id><pub-id pub-id-type="pmcid">PMC2174763</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwok</surname><given-names>CS</given-names></name><name name-style="western"><surname>Arthur</surname><given-names>AK</given-names></name><name name-style="western"><surname>Anibueze</surname><given-names>CI</given-names></name><etal>et al</etal></person-group><article-title>Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis</article-title><source>Am J Gastroenterol</source><year>2012</year><volume>107</volume><fpage>1011</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/ajg.2012.108</pub-id><pub-id pub-id-type="pmid">22525304</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lam</surname><given-names>JR</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>JL</given-names></name><name name-style="western"><surname>Quesenberry</surname><given-names>CP</given-names></name><etal>et al</etal></person-group><article-title>Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency</article-title><source>Gastroenterology</source><year>2017</year><volume>152</volume><fpage>821</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2016.11.023</pub-id><pub-id pub-id-type="pmid">27890768</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalili</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>ES</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>BC</given-names></name><etal>et al</etal></person-group><article-title>Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study</article-title><source>BMJ</source><year>2012</year><volume>344</volume><elocation-id>e372</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.e372</pub-id><pub-id pub-id-type="pmid">22294756</pub-id><pub-id pub-id-type="pmcid">PMC3269660</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Praga</surname><given-names>M</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>E</given-names></name></person-group><article-title>Acute interstitial nephritis</article-title><source>Kidney Int</source><year>2010</year><volume>77</volume><fpage>956</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1038/ki.2010.89</pub-id><pub-id pub-id-type="pmid">20336051</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Francisco</surname><given-names>ALM</given-names></name><name name-style="western"><surname>Varas</surname><given-names>J</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients</article-title><source>Kidney Int Rep</source><year>2018</year><volume>3</volume><fpage>374</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.ekir.2017.11.001</pub-id><pub-id pub-id-type="pmid">29725641</pub-id><pub-id pub-id-type="pmcid">PMC5932134</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bowe</surname><given-names>B</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study</article-title><source>BMJ</source><year>2019</year><volume>365</volume><elocation-id>l1580</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.l1580</pub-id><pub-id pub-id-type="pmid">31147311</pub-id><pub-id pub-id-type="pmcid">PMC6538974</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romdhane</surname><given-names>H</given-names></name><name name-style="western"><surname>Ayadi</surname><given-names>S</given-names></name><name name-style="western"><surname>Elleuch</surname><given-names>N</given-names></name><etal>et al</etal></person-group><article-title>Effect of long-term proton pump inhibitors on bone mineral density</article-title><source>Tunis Med</source><year>2018</year><volume>96</volume><fpage>193</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">30325487</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glaser</surname><given-names>DL</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>FS</given-names></name></person-group><article-title>Osteoporosis. Definition and clinical presentation</article-title><source>Spine (Phila Pa 1986)</source><year>1997</year><volume>22</volume><pub-id pub-id-type="doi">10.1097/00007632-199712151-00003</pub-id><pub-id pub-id-type="pmid">9431639</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thong</surname><given-names>BKS</given-names></name><name name-style="western"><surname>Ima-Nirwana</surname><given-names>S</given-names></name><name name-style="western"><surname>Chin</surname><given-names>KY</given-names></name></person-group><article-title>Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved</article-title><source>Int J Environ Res Public Health</source><year>2019</year><volume>16</volume><elocation-id>1571</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph16091571</pub-id><pub-id pub-id-type="pmid">31060319</pub-id><pub-id pub-id-type="pmcid">PMC6540255</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leontiadis</surname><given-names>GI</given-names></name><name name-style="western"><surname>Moayyedi</surname><given-names>P</given-names></name></person-group><article-title>Proton pump inhibitors and risk of bone fractures</article-title><source>Curr Treat Options Gastroenterol</source><year>2014</year><volume>12</volume><fpage>414</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/s11938-014-0030-y</pub-id><pub-id pub-id-type="pmid">25209137</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>B</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Proton-pump inhibitors and risk of fractures: an update meta-analysis</article-title><source>Osteoporos Int</source><year>2016</year><volume>27</volume><fpage>339</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1007/s00198-015-3365-x</pub-id><pub-id pub-id-type="pmid">26462494</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vestergaard</surname><given-names>P</given-names></name><name name-style="western"><surname>Rejnmark</surname><given-names>L</given-names></name><name name-style="western"><surname>Mosekilde</surname><given-names>L</given-names></name></person-group><article-title>Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture</article-title><source>Calcif Tissue Int</source><year>2006</year><volume>79</volume><fpage>76</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1007/s00223-006-0021-7</pub-id><pub-id pub-id-type="pmid">16927047</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poly</surname><given-names>TN</given-names></name><name name-style="western"><surname>Islam</surname><given-names>MM</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H-C</given-names></name><etal>et al</etal></person-group><article-title>Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies</article-title><source><italic toggle="yes">Osteoporos Int</italic></source><year>2019</year><volume>30</volume><fpage>103</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1007/s00198-018-4788-y</pub-id><pub-id pub-id-type="pmid">30539272</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muriithi</surname><given-names>AK</given-names></name><name name-style="western"><surname>Leung</surname><given-names>N</given-names></name><name name-style="western"><surname>Valeri</surname><given-names>AM</given-names></name><etal>et al</etal></person-group><article-title>Biopsy-proven acute interstitial nephritis, 1993-2011: a case series</article-title><source>Am J Kidney Dis</source><year>2014</year><volume>64</volume><fpage>558</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2014.04.027</pub-id><pub-id pub-id-type="pmid">24927897</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Behrman</surname><given-names>RE</given-names></name><name name-style="western"><surname>Benner</surname><given-names>JS</given-names></name><name name-style="western"><surname>Brown</surname><given-names>JS</given-names></name><etal>et al</etal></person-group><article-title>Developing the Sentinel System--a national resource for evidence development</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><fpage>498</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1056/NEJMp1014427</pub-id><pub-id pub-id-type="pmid">21226658</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klatte</surname><given-names>DCF</given-names></name><name name-style="western"><surname>Gasparini</surname><given-names>A</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><etal>et al</etal></person-group><article-title>Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease</article-title><source>Gastroenterology</source><year>2017</year><volume>153</volume><fpage>702</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2017.05.046</pub-id><pub-id pub-id-type="pmid">28583827</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bowe</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD</article-title><source><italic toggle="yes">J Am Soc Nephrol</italic></source><year>2016</year><volume>27</volume><fpage>3153</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1681/ASN.2015121377</pub-id><pub-id pub-id-type="pmid">27080976</pub-id><pub-id pub-id-type="pmcid">PMC5042677</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ajmera</surname><given-names>AV</given-names></name><name name-style="western"><surname>Shastri</surname><given-names>GS</given-names></name><name name-style="western"><surname>Gajera</surname><given-names>MJ</given-names></name><etal>et al</etal></person-group><article-title>Suboptimal response to ferrous sulfate in iron-deficient patients taking omeprazole</article-title><source>Am J Ther</source><year>2012</year><volume>19</volume><fpage>185</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/MJT.0b013e3181f9f6d2</pub-id><pub-id pub-id-type="pmid">21150767</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dado</surname><given-names>DN</given-names></name><name name-style="western"><surname>Loesch</surname><given-names>EB</given-names></name><name name-style="western"><surname>Jaganathan</surname><given-names>SP</given-names></name></person-group><article-title>A Case of Severe Iron Deficiency Anemia Associated with Long-Term Proton Pump Inhibitor Use</article-title><source>Curr Ther Res Clin Exp</source><year>2017</year><volume>84</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1016/j.curtheres.2017.01.003</pub-id><pub-id pub-id-type="pmid">28761572</pub-id><pub-id pub-id-type="pmcid">PMC5522969</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imai</surname><given-names>R</given-names></name><name name-style="western"><surname>Higuchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Morimoto</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Iron Deficiency Anemia Due to the Long-term Use of a Proton Pump Inhibitor</article-title><source>Intern Med</source><year>2018</year><volume>57</volume><fpage>899</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.9554-17</pub-id><pub-id pub-id-type="pmid">29151538</pub-id><pub-id pub-id-type="pmcid">PMC5891535</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>MD</given-names></name></person-group><article-title>Proton Pump Inhibitors&#8217; Use and Risk of Iron Deficiency Anaemia: A Systematic Review and Meta-analysis</article-title><source><italic toggle="yes">Curr Rev Clin Exp Pharmacol</italic></source><year>2023</year><volume>18</volume><fpage>158</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.2174/2772432817666220307121220</pub-id><pub-id pub-id-type="pmid">35255801</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arora</surname><given-names>P</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name><name name-style="western"><surname>Golzy</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Proton pump inhibitors are associated with increased risk of development of chronic kidney disease</article-title><source>BMC Nephrol</source><year>2016</year><volume>17</volume><elocation-id>112</elocation-id><pub-id pub-id-type="doi">10.1186/s12882-016-0325-4</pub-id><pub-id pub-id-type="pmid">27487959</pub-id><pub-id pub-id-type="pmcid">PMC4973085</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazarus</surname><given-names>B</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>FP</given-names></name><etal>et al</etal></person-group><article-title>Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease</article-title><source>JAMA Intern Med</source><year>2016</year><volume>176</volume><fpage>238</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2015.7193</pub-id><pub-id pub-id-type="pmid">26752337</pub-id><pub-id pub-id-type="pmcid">PMC4772730</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>THE ARIC INVESTIGATORS</collab></person-group><article-title>THE ATHEROSCLEROSIS RISK IN COMMUNIT (ARIC) STUDY: DESIGN AND OBJECTIVES</article-title><source>Am J Epidemiol</source><year>1989</year><volume>129</volume><fpage>687</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a115184</pub-id><pub-id pub-id-type="pmid">2646917</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moride</surname><given-names>Y</given-names></name><name name-style="western"><surname>Abenhaim</surname><given-names>L</given-names></name></person-group><article-title>Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research</article-title><source>J Clin Epidemiol</source><year>1994</year><volume>47</volume><fpage>731</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/0895-4356(94)90170-8</pub-id><pub-id pub-id-type="pmid">7722586</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brewster</surname><given-names>UC</given-names></name><name name-style="western"><surname>Perazella</surname><given-names>MA</given-names></name></person-group><article-title>Proton pump inhibitors and the kidney: critical review</article-title><source>Clin Nephrol</source><year>2007</year><volume>68</volume><fpage>65</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.5414/cnp68065</pub-id><pub-id pub-id-type="pmid">17722704</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuukkanen</surname><given-names>J</given-names></name><name name-style="western"><surname>V&#228;&#228;n&#228;nen</surname><given-names>HK</given-names></name></person-group><article-title>Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro</article-title><source>Calcif Tissue Int</source><year>1986</year><volume>38</volume><fpage>123</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1007/BF02556841</pub-id><pub-id pub-id-type="pmid">3006888</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Briganti</surname><given-names>SI</given-names></name><name name-style="western"><surname>Naciu</surname><given-names>AM</given-names></name><name name-style="western"><surname>Tabacco</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>Proton Pump Inhibitors and Fractures in Adults: A Critical Appraisal and Review of the Literature</article-title><source>Int J Endocrinol</source><year>2021</year><volume>2021</volume><elocation-id>8902367</elocation-id><pub-id pub-id-type="doi">10.1155/2021/8902367</pub-id><pub-id pub-id-type="pmid">33510787</pub-id><pub-id pub-id-type="pmcid">PMC7822697</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Hoorn</surname><given-names>MMC</given-names></name><name name-style="western"><surname>Tett</surname><given-names>SE</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>OJ</given-names></name><etal>et al</etal></person-group><article-title>The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study</article-title><source>Bone</source><year>2015</year><volume>81</volume><fpage>675</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2015.08.024</pub-id><pub-id pub-id-type="pmid">26319499</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoff</surname><given-names>M</given-names></name><name name-style="western"><surname>Skovlund</surname><given-names>E</given-names></name><name name-style="western"><surname>Skurtveit</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Proton pump inhibitors and fracture risk. The HUNT study, Norway</article-title><source>Osteoporos Int</source><year>2020</year><volume>31</volume><fpage>109</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1007/s00198-019-05206-0</pub-id><pub-id pub-id-type="pmid">31741023</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J-H</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S-Y</given-names></name><etal>et al</etal></person-group><article-title>Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease</article-title><source>BMC Geriatr</source><year>2020</year><volume>20</volume><fpage>407</fpage><pub-id pub-id-type="doi">10.1186/s12877-020-01794-3</pub-id><pub-id pub-id-type="pmid">33059626</pub-id><pub-id pub-id-type="pmcid">PMC7565339</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>J</given-names></name><name name-style="western"><surname>Chan</surname><given-names>AT</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>Association between proton pump inhibitors use and risk of hip fracture: A general population-based cohort study</article-title><source><italic toggle="yes">Bone</italic></source><year>2020</year><volume>139</volume><fpage>115502</fpage><pub-id pub-id-type="doi">10.1016/j.bone.2020.115502</pub-id><pub-id pub-id-type="pmid">32593677</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Youn</surname><given-names>K</given-names></name><name name-style="western"><surname>Choi</surname><given-names>N-K</given-names></name><etal>et al</etal></person-group><article-title>A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate</article-title><source>J Gastroenterol</source><year>2013</year><volume>48</volume><fpage>1016</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1007/s00535-012-0722-9</pub-id><pub-id pub-id-type="pmid">23307040</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cea Soriano</surname><given-names>L</given-names></name><name name-style="western"><surname>Ruig&#243;mez</surname><given-names>A</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Study of the Association Between Hip Fracture and Acid&#8208;Suppressive Drug Use in a <sc>uk</sc> Primary Care Setting</article-title><source><italic toggle="yes">Pharmacotherapy</italic></source><year>2014</year><volume>34</volume><fpage>570</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1002/phar.1410</pub-id><pub-id pub-id-type="pmid">24634193</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>J</given-names></name><name name-style="western"><surname>Heller</surname><given-names>DA</given-names></name><name name-style="western"><surname>Ahern</surname><given-names>FM</given-names></name><etal>et al</etal></person-group><article-title>The relationship between proton pump inhibitor adherence and fracture risk in the elderly</article-title><source>Calcif Tissue Int</source><year>2014</year><volume>94</volume><fpage>597</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1007/s00223-014-9855-6</pub-id><pub-id pub-id-type="pmid">24706060</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>AL</given-names></name><name name-style="western"><surname>Black</surname><given-names>MH</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>JL</given-names></name><etal>et al</etal></person-group><article-title>Proton-pump inhibitor use and hip fractures in men: a population-based case-control study</article-title><source>Ann Epidemiol</source><year>2014</year><volume>24</volume><fpage>286</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.annepidem.2014.01.004</pub-id><pub-id pub-id-type="pmid">24507954</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harding</surname><given-names>BN</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>NS</given-names></name><name name-style="western"><surname>Walker</surname><given-names>RL</given-names></name><etal>et al</etal></person-group><article-title>Proton pump inhibitor use and the risk of fractures among an older adult cohort</article-title><source>Pharmacoepidemiol Drug Saf</source><year>2018</year><volume>27</volume><fpage>596</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1002/pds.4406</pub-id><pub-id pub-id-type="pmid">29493043</pub-id><pub-id pub-id-type="pmcid">PMC5984154</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brozek</surname><given-names>W</given-names></name><name name-style="western"><surname>Reichardt</surname><given-names>B</given-names></name><name name-style="western"><surname>Zwerina</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Higher dose but not low dose proton pump inhibitors are associated with increased risk of subsequent hip fractures after first hip fracture: A nationwide observational cohort study</article-title><source>Bone Rep</source><year>2019</year><volume>10</volume><elocation-id>100204</elocation-id><pub-id pub-id-type="doi">10.1016/j.bonr.2019.100204</pub-id><pub-id pub-id-type="pmid">30993153</pub-id><pub-id pub-id-type="pmcid">PMC6451165</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gray</surname><given-names>SL</given-names></name><name name-style="western"><surname>LaCroix</surname><given-names>AZ</given-names></name><name name-style="western"><surname>Larson</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women&#8217;s Health Initiative</article-title><source>Arch Intern Med</source><year>2010</year><volume>170</volume><fpage>765</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1001/archinternmed.2010.94</pub-id><pub-id pub-id-type="pmid">20458083</pub-id><pub-id pub-id-type="pmcid">PMC4240017</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moberg</surname><given-names>LME</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>PM</given-names></name><name name-style="western"><surname>Samsioe</surname><given-names>G</given-names></name><etal>et al</etal></person-group><article-title>Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study</article-title><source>Maturitas</source><year>2014</year><volume>78</volume><fpage>310</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.maturitas.2014.05.019</pub-id><pub-id pub-id-type="pmid">24958166</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J-H</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y-M</given-names></name><name name-style="western"><surname>Jung</surname><given-names>J-H</given-names></name><etal>et al</etal></person-group><article-title>Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study</article-title><source><italic toggle="yes">Bone</italic></source><year>2020</year><volume>135</volume><fpage>115306</fpage><pub-id pub-id-type="doi">10.1016/j.bone.2020.115306</pub-id><pub-id pub-id-type="pmid">32126312</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reyes</surname><given-names>C</given-names></name><name name-style="western"><surname>Formiga</surname><given-names>F</given-names></name><name name-style="western"><surname>Coderch</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region</article-title><source>Bone</source><year>2013</year><volume>52</volume><fpage>557</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2012.09.028</pub-id><pub-id pub-id-type="pmid">23023097</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>JR</given-names></name><name name-style="western"><surname>Barre</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Long-Term Proton Pump Inhibitor Therapy and Falls and Fractures in Elderly Women: A Prospective Cohort Study</article-title><source>J Bone Miner Res</source><year>2014</year><volume>29</volume><fpage>2489</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1002/jbmr.2279</pub-id><pub-id pub-id-type="pmid">24825180</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamaguchi</surname><given-names>K</given-names></name><name name-style="western"><surname>Kurihara</surname><given-names>T</given-names></name><name name-style="western"><surname>Fujimoto</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Associations among Bone Mineral Density, Physical Activity and Nutritional Intake in Middle-Aged Women with High Levels of Arterial Stiffness: A Pilot Study</article-title><source>Int J Environ Res Public Health</source><year>2020</year><volume>17</volume><elocation-id>1620</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph17051620</pub-id><pub-id pub-id-type="pmid">32138200</pub-id><pub-id pub-id-type="pmcid">PMC7084750</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>M-S</given-names></name><name name-style="western"><surname>Li</surname><given-names>H-L</given-names></name><name name-style="western"><surname>Hung</surname><given-names>T-H</given-names></name><etal>et al</etal></person-group><article-title>Vitamin D intake and its food sources in Taiwanese</article-title><source>Asia Pac J Clin Nutr</source><year>2008</year><volume>17</volume><fpage>397</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">18818159</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Dietary calcium intake and food sources among Chinese adults in CNTCS</article-title><source>PLoS One</source><year>2018</year><volume>13</volume><elocation-id>e0205045</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0205045</pub-id><pub-id pub-id-type="pmid">30273413</pub-id><pub-id pub-id-type="pmcid">PMC6166981</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greendale</surname><given-names>GA</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Shieh</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Leisure time physical activity and bone mineral density preservation during the menopause transition and postmenopause: a longitudinal cohort analysis from the Study of Women&#8217;s Health Across the Nation (SWAN)</article-title><source><italic toggle="yes">Lancet Reg Health Am</italic></source><year>2023</year><volume>21</volume><elocation-id>100481</elocation-id><pub-id pub-id-type="doi">10.1016/j.lana.2023.100481</pub-id><pub-id pub-id-type="pmid">37008197</pub-id><pub-id pub-id-type="pmcid">PMC10060105</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zileli</surname><given-names>M</given-names></name><name name-style="western"><surname>Fornari</surname><given-names>M</given-names></name><name name-style="western"><surname>Costa</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>Epidemiology, natural course, and preventive measures of osteoporotic vertebral fractures: WFNS Spine Committee Recommendations</article-title><source>J Neurosurg Sci</source><year>2022</year><volume>66</volume><fpage>282</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.23736/S0390-5616.22.05643-0</pub-id><pub-id pub-id-type="pmid">35301844</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>L-Y</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>K-S</given-names></name><name name-style="western"><surname>Peng</surname><given-names>J-K</given-names></name><etal>et al</etal></person-group><article-title>The development of Taiwan Fracture Liaison Service network</article-title><source>Osteoporos Sarcopenia</source><year>2018</year><volume>4</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.afos.2018.06.001</pub-id><pub-id pub-id-type="pmid">30775542</pub-id><pub-id pub-id-type="pmcid">PMC6362955</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Courtney</surname><given-names>MG</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J</given-names></name><name name-style="western"><surname>Quintero</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Childhood Family Environment and Osteoporosis in a Population-Based Cohort Study of Middle-to Older-Age Americans</article-title><source>JBMR Plus</source><year>2023</year><volume>7</volume><elocation-id>e10735</elocation-id><pub-id pub-id-type="doi">10.1002/jbm4.10735</pub-id><pub-id pub-id-type="pmid">37197319</pub-id><pub-id pub-id-type="pmcid">PMC10184016</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kennedy-Hendricks</surname><given-names>A</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>H</given-names></name><name name-style="western"><surname>Thornton</surname><given-names>RJ</given-names></name><etal>et al</etal></person-group><article-title>Intergenerational Social Networks and Health Behaviors Among Children Living in Public Housing</article-title><source>Am J Public Health</source><year>2015</year><volume>105</volume><fpage>2291</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.2105/AJPH.2015.302663</pub-id><pub-id pub-id-type="pmid">26378821</pub-id><pub-id pub-id-type="pmcid">PMC4605160</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran-Duy</surname><given-names>A</given-names></name><name name-style="western"><surname>Connell</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Vanmolkot</surname><given-names>FH</given-names></name><etal>et al</etal></person-group><article-title>Use of proton pump inhibitors and risk of iron deficiency: a population-based case-control study</article-title><source>J Intern Med</source><year>2019</year><volume>285</volume><fpage>205</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1111/joim.12826</pub-id><pub-id pub-id-type="pmid">30141278</pub-id></element-citation></ref></ref-list><sec sec-type="data-availability"><title>Data availability statement</title><p>Data may be obtained from a third party and are not publicly available.</p></sec></back></article></pmc-articleset>